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ABSTRACT

Author: Wang, Chao. PhD
Institution: Purdue University
Degree Received: December 2017
Title: Functional Characterization of Two Novel Myofiber Type-Specific Non-histone Protein
Methyltransferases
Major Professor: Shihuan Kuang
Skeletal muscles are composed of muscle cells or myofibers which are classified as four types (I,
IIa, IIx/d, and IIb), with different physiological, biochemical, structural and metabolic
characteristics. The molecular regulation of myofiber identify is not completely understood. I
identified methyltransferase like 21 (Mettl21) e and Mettl21c as the type IIb and type I myofiberspecific protein, respectively. The aim of this dissertation was to determine the function of
Mettl21e and Mettl21c in regulating myofiber identity.
In the first part of the thesis, I used in silico approaches to identify Mettl21e as one of the top upregulated genes in myostatin knockout (KO) mice, which exhibit robust muscle hypertrophy and
increased proportion of IIb myofibers. Interestingly, the expression of Mettl21e is not directly
regulated by myostatin, and its high level of expression in myostatin KO mice is a consequence
of increased number of IIb myofibers. I then used gain-of-function and loss-of-function
approaches to study the role of Mettl21e in muscle. Overexpression and knockdown of Mettl21e
in cultured myoblasts increases and decreases the size of myotubes, respectively. Transgenic
overexpression of Mettl21e in skeletal muscles of mice not only increases myofiber size of
normally innervated muscles, but also ameliorates wasting of denervated muscles. By contrast,
knockout of Mettl21e reduces the size of IIb myofibers without affecting fiber composition.
Mass spectrometry reveals that Mettl21e interacts with subunits of 26S proteasome protein
degradation system. Overexpression and knockout of Mettl21e suppresses and increases the
activity of 26S proteasome, respectively. Notably, proteasome inhibitor rescues the size of
Mettl21e-knockdown myotubes. These results establish a role of Mettl21e in increasing IIb
myofiber size through decreasing proteasome activity.

xii
In the second part of the thesis, I focused on Mettl21c, a paralog of Mettl21e. I identified
Mettl21c as a type I myofiber specific protein that tri-methylates heat shock protein 8 (Hspa8) at
lysine-561 to increase its stability. The stabilized Hspa8 promotes selective degradation of
MEF2A and MEF2D through chaperone-mediated autophagy. Overexpression of Mettl21c in
myoblasts increases the level of Hspa8 and reduces the levels of MEF2A and MEF2D.
Conversely, knockout of Mettl21c reduces the trimethylation of Hspa8 in type I-myofiber,
leading to lower levels of Hspa8, higher levels of MEF2 proteins and increased expressions of
slow muscle-specific genes. These results establish a role of Mettl21c in regulating type I
myofiber homeostasis and function.
In summary, my studies uncover the functions of two novel methyltransferases, extending the
understanding of non-histone methyltransferases in biological process, and demonstrating the
importance of myofiber type-specific proteins in regulating myofiber identity.
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CHAPTER 1.

1.1

LITERATURE REVIEW

Structure and function of skeletal muscle

Muscle is a soft tissue and functions to produce force and motion. A human body contains at
least 650 muscles which are classified into three types: skeletal muscle, cardiac muscle and
smooth muscle. Skeletal muscles are muscles attached to skeletons by tendons. Skeletal muscle
makes up 40 percent of human body mass, provides mechanical supports of motor movements,
and contributes to glucose, fatty acid and lactate metabolism (Schiaffino and Reggiani, 2011).
Skeletal muscles are composed of clusters of muscle cells (myocytes or myofibers). A bundle of
myofibers are surrounded by a type of connective tissue, or the perimysium to form a fascicle.
And multiple fascicles are surrounded by epimysium to form a skeletal muscle.
The myofiber has several special histological features. First, It has a long and spindle shape. The
length ranges from 0.1 to 30 cm; and the diameter ranges from 10 to 100 µm. Second, it contains
multiple nuclei. Third, its cell membrane, or the sarcolemma invaginates into the cytoplasm,
forming a specialized structure, transverse tubule (T-tubule). T-tubule contains large amounts of
ion channels, allowing for the rapid travelling of electrical impulse (Al-Qusairi and Laporte,
2011). Fourth, its cytoplasm, or the sarcoplasm contains the sarcoplasmic reticulum (SR) which
is a specialized endoplasmic reticulum (Lanner et al., 2010). SR is responsible for absorption,
storage and release of Ca2+ through sarcoplasmic reticulum calcium pump (SERCA),
calsequestrin and ryanodine receptor (RyR), respectively. In addition, sarcoplasm contains rodlike and elongated protein molecules, myofibrils, which are aligned in parallel and extend the full
length of the myofiber.
The myofibril is composed of protein chains called myofilaments. There are two types of
myofilaments, thin and thick. Thin myofilament (F-actin) consists of actin polymers integrated
with tropomyosin polymers, nebulin polymers and troponin complex and has a helically
intertwined shape. Thick myofilament consists of myosin molecules, with a shape of a globular
head and a long tail. The myosin is a hexamers consisting of two myosin heavy chain (Myh) and
two pairs of myosin light chain (Myl). Myh have different isoforms. Reducing Myh isoforms
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interrupts muscle function in Drosophila (Wells et al., 1996), indicating that Myh isoform is one
of the major determinants for muscle contractile performance. Myh contains ATPase domain,
and different myosin isoforms have different ATPase activity (Brooke and Kaiser, 1970; Guth
and Samaha, 1969). As ATP provides energy for motor movement, Myh could possibly
influence contractile performance through its ATPase domain.
Myofilaments, and other molecules, like α-actinin, myomesin, C-protein, and titin are organized
together to form repeating units of the myofibril, sarcomeres (Hwang and Sykes, 2015). The
boundary of a sarcomere is Z-disc which is formed by layers of crosslinked α-actinin. The Z-disc
is the anchoring point of thin filaments and titin. The middle of sarcomere is M-band which is
formed by Myomesin and C-protein. The M-band is attached with thick myofilaments and titin.
Titin not only connects the Z-disc and M-band, it also functions to stabilize thick myofilaments
to prevent overstretching of the sarcomere. The organization of sarcomere makes it appear as
alternating dark and light bands under electron microscopy.
The sarcomere is also the functional unit of a skeletal muscle (Hwang and Sykes, 2015). Each
myofiber is monoinnervated by a motor neuron which transmits electrical impulses to the
myofiber. The electrical impulse travels along T-tubules until it reaches the SR to activate RyR,
inducing a large increase of intracellular Ca2+. Ca2+ ions bind with troponin complex in
sarcomere to alter the structure of the tropomyosin, revealing myosin binding sites in F-actin.
The heads of myosin molecules then bind to actin polymers, forming cross bridges. During the
binding of myosin and actin, ATP bound to the Myh is hydrolyzed into ADP and phosphate. The
released energy drives the myosin heads towards actin polymers. Then the F-actin is pulled along,
causing the sarcomere to contract (shorten the distance between Z-disc and M-band). When
muscle is about to relax, Ca2+ ions are carried away from the troponin complex, and the
tropomyosin bind to the myosin binding sites on the F-actin, interrupting the myosin-actin
binding. In addition, a new ATP replaces ADP and binds the myosin head to reduce the affinity
of myosin for actin, ready for another contraction cycle.
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1.2

Myofiber types in skeletal muscle

Mammalian skeletal muscles are heterogeneous. In the 19 th century, skeletal muscles were
classified as red muscles and white muscles. The red color comes from an iron-/oxygen-binding
protein called myoglobin. Red muscles have slower twitch movement than white muscles, so red
muscles were also defined as slow-twitch muscles and white muscles as fast-twitch muscles
(Needham, 1926). With the development of electron microscopy at the end of 1960s, the
structure of skeletal muscles was studied. Red muscles have more mitochondria and thicker Zlines than white muscles, which are correlated with the higher fatigue resistance of red muscles
(Schiaffino et al., 1970). In contrast, white muscles have more developed SR, leading to the
higher speed of contraction (Schiaffino et al., 1970).
Myofibers are also heterogeneous (Edstrom and Kugelberg, 1968). Myofibers are classified as
type I, type IIa and type IIb using histochemistry staining for myosin adenosine triphosphatase
(ATPase) (Brooke and Kaiser, 1970; Guth and Samaha, 1969). In addition, myofibers are also
classified as slow oxidative, fast-twitch oxidative glycolytic, and fast-twitch glycolytic myoﬁbers
by detecting oxidative capacity (cytochrome concentration and succinate dehydrogenase activity)
and glycolytic capacity (glycogen concentration, lactate dehydrogenase, phosphorylase and αglycerophosphate dehydrogenase activities) (Peter et al., 1972). At the end of 1980s, myofibers
were further identified as type I, IIa, IIx/d or IIb using monoclonal antibodies against Myh
isoforms (Myh7, Myh2, Myh1 or Myh4) (Schiaffino et al., 1989).
Different types of myofibers have distinct physiological and metabolic characteristics (Schiaffino
and Reggiani, 2011). The contractile speed of myofibers ranks in the order of IIb > IIx > IIa > I,
while the fatigue resistance of myofibers is negatively correlated with the contractile speed
(Schiaffino and Reggiani, 2011). Biochemically and metabolically, I and IIa myofibers have high
oxidative capacity with a large number of mitochondria. In contrast, IIx and IIb myofibers
mainly utilize glycolysis to generate ATP. Besides the physiological and metabolic differences,
the size of myofibers are generally in the order of IIb > IIx > IIa > I (van Wessel et al., 2010).
The physiological performance of a myofiber is comprehensively determined by its cellular
structure, ATPase activity and metabolic condition. Type I myofiber is the slow-twitch myofiber
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which has low ATPase activity. The low ATPase activity guarantees that the type I myofiber has
time to use the time-consuming oxidative phosphorylation to generate ATP. Ample supply of
ATP makes the type I myofiber have high fatigue resistance. In contrast, type II myofibers are
fast-twitch and have high ATPase activity, so they deplete their ATP pool quickly and then use a
time-saving way, the glycolysis to generate ATP. The small amount of ATP generated by
glycolysis cannot support endurance muscle contraction, so the fast-twitch myofiber has low
fatigue resistance. The well-developed SR in type II myofibers provides enough Ca 2+ for fast
muscle contraction.

1.3
1.3.1

Skeletal myogenesis and its molecular regulations

Embryonic skeletal myogenesis

Skeletal muscle is originated from mesoderm, one primary germ layer that forms during
gastrulation when the epiblast is reorganized into a multilayered structure. Mesoderm is specified
into different types, including chorda- mesoderm, paraxial-mesoderm, intermediate-mesoderm
and later plate-mesoderm. The paraxial-mesoderm flanks neural tube and is further segmented
into somites. The segmentation of paraxial-mesoderm is controlled by Notch, FGF and Wnt
signaling pathways (Hubaud and Pourquie, 2014). Somites become compartmentalized to
dermomyotome which gives rise to the skeletal muscle, dermis of the back, and sclerotome. The
fates of somites are mainly regulated through Wnt, BMP and Shh signaling pathways (Yusuf and
Brand-Saberi, 2006).
Myogenic progenitors are derived from cells expressing the paired box transcription factor, Pax3,
in the dermomyotome (Kassar-Duchossoy et al., 2005; Relaix et al., 2005). Pax3 + cells in
dorsomedial lip (DML) of the dermomyotome begin to express a myogenic regulatory factor
(MRF) Myf5, which marks the beginning of primary myogenesis. The Myf5+ cells are
translocated and elongated in the AP axis of the embryo to form the primary myotome between
the dermomyotome dorsally and the sclerotome ventrally (Gros et al., 2004). Later more Myf5 +
cells from the other three lips of the dermomyotome are progressively added to the myotome and
these cells fuse to existing myocytes leading to the expression of embryonic (Myh3) and slow
(Myh7) Myh (Gros et al., 2004). Then Pax3+ myogenic progenitors originated from the central
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portion of the dermomyotome (cDM) enter the primary myotome after an epithelial-tomesenchyme transition (EMT) (Sieiro-Mosti et al., 2014). These Pax3 + cells from cDM will
mainly contribute to secondary myogenesis.
The secondary myogenesis happens from E14.5-E20.5 (mouse), when part of Pax3 + cells begins
to express Pax7 and downregulates Pax3, and then the Pax7+ cells proliferate, and fuse among
them or to the myofibers formed in primary myogenesis. During secondary myogenesis,
myofibers start to express fast Myh isoforms (Chal and Pourquie, 2017). At the end of the fetal
stage, Pax7+ cells locate underneath the basal lamina and outside the fiber, a characteristic of
satellite cells (Kassar-Duchossoy et al., 2005). Once the muscle has matured, these Pax7 + cells
enter a quiescence state as satellite cells (Bentzinger et al., 2012), which are responsible for
postnatal muscle growth and regeneration (Kuang and Rudnicki, 2008).
1.3.2

Postnatal skeletal myogenesis

Satellite cells are responsible for postnatal skeletal myogenesis. In response to postnatal skeletal
muscle injury, satellite cells exit their quiescent state and start to proliferate in either a symmetric
or asymmetric way (Kuang et al., 2007). Symmetric proliferation results in two activated satellite
cells, leading to the expansion of the myogenic cells which undergo fusion to form functional
regenerated myofibers. In contrast, asymmetric proliferation produces an activated satellite cell
and a quiescent satellite cell, leading to not only the expansion of myogenic cells but also the
replenishment of the satellite cell pool. The asymmetric proliferation is also called self-renewal
of satellite cell.
Pax7 regulates the expansion and differentiation of satellite cells during both neonatal and adult
myogenesis (von Maltzahn et al., 2013). Loss of Pax7 induces the progressive depletion of
satellite cells (Seale et al., 2000; von Maltzahn et al., 2013). Besides Pax7, the identity of
satellites cells is also regulated by Notch signaling. Satellite cells express Notch receptors
Notch1, Notch2, and Notch3, and Notch ligands Dll1 and Jag1 (Relaix and Marcelle, 2009).
Myofibers express Notch ligands Dll1, Dll3, Dll4, Jag1 and Jag2. Once Notch receptors and
ligands are interacted, Notch extracellular and intracellular domains are cleaved, and the Notch
Intracellular Domain (NICD) translocates to the nucleus to form complex with RBP-Jκ (CBF1)
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and activates the transcription of target genes (Lai, 2004). Notch signaling guides homing of
satellite cells and stimulates them to contribute to their niche through regulating the expression
of adhesion molecules and basal lamina components (Brohl et al., 2012). In addition, Notch
signaling maintains self-renewal of satellite cells through regulating the expression of Pax7 (Wen
et al., 2012). Disruption of Notch signaling leads to precocious differentiation of myogenic
precursors and depletion of satellite cells (Schuster-Gossler et al., 2007; Vasyutina et al., 2007).
With age, Notch signaling becomes weakening due to diminished Dll1 expression in myofibers
and in satellite cells (Conboy et al., 2003). Consistently, Notch activation successfully improves
the regeneration of aged muscle (Carlson et al., 2008; Conboy et al., 2003).
Besides satellite cells, there are other cell types that have myogenic potential (Sirabella et al.,
2013; Tedesco et al., 2010). These nonsatellite cell muscle precursors include PW1 + muscle
interstitial cells (Mitchell et al., 2010), β4 integrin+ muscle interstitial cells (Liadaki et al., 2012),
CD133+ hematopoietic stem cells (Torrente et al., 2004), mesoangioblasts (Sampaolesi et al.,
2003), pericytes (Dellavalle et al., 2007), and adipose-tissue-derived cells (Di Rocco et al., 2006).
1.3.3

Basic Helix-loop-Helix (bHLH) factors in skeletal myogenesis

Myogenesis is a highly orchestrated process regulated by several basic Helix-loop-Helix (bHLH)
factors known as MRFs (Olson and Klein, 1994; Pownall et al., 2002). Myf5, MyoD, Myog and
Myf6 (Mrf4) are muscle-specific MRFs that orchestrate the process of myogenesis. Each MRF
alone can transform nonmyogenic fibroblastic cells into myoblasts (Braun et al., 1989; Davis et
al., 1987; Edmondson and Olson, 1989; Rhodes and Konieczny, 1989). Myf5, MyoD and Myf6
play redundant roles in committing somite derived cells to myoblasts (Kassar-Duchossoy et al.,
2004; Rudnicki et al., 1993). MyoD and Myf6 also initiate the onset of myogenic differentiation
(Rawls et al., 1998). Myog governs myoblast terminal differentiation (Hasty et al., 1993). MRFs
typically form heterodimers with E proteins. The heterodimers subsequently bind to a hexameric
consensus DNA sequence, the E-box, to activate the transcription of target genes. Achaete-scute
complex homolog 2 (Ascl2) and basic helix-loop-helix family member e40 (Bhlhe40) are bHLH
factors as well, while Ascl2 and Bhlhe40 inhibit myogenesis by antagonizing the activity of
MRFs (Wang et al., 2015; Wang et al., 2017b). Ascl2 and Bhlhe40 compete with MRFs for
binding to E-boxes in the promoters of muscle genes, without activating gene transcription.
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Ascl2 also forms heterodimer with E proteins to sequester their transcriptional activity on MRFs.
The modulation of MRFs activity is important for muscle development by preventing precocious
differentiation and maintaining muscle stem cell reservoir.
1.3.4

Innervation and skeletal myogenesis

Innervation is a crucial step for the maintenance of muscle mass and establishment of myofiber
type. Loss of innervation leads to the loss of voluntary function and the atrophy and degeneration
of myofibers (Carlson, 2014). The axon of motor neurons from the spinal cord forms synaptic
contact with newly formed myofibers during fetal stages – as early as E14.5 in mouse limbs
(Kuang and Rudnicki, 2008). Myofibers are polyinnervated at birth. During 2-4 weeks postnatal,
the polyinnervated myofibers become monoinnervated after a process of axon pruning.
Meanwhile, the synapse neuromuscular junction (NMJ) goes through a morphology and
molecular maturation process (Shi et al., 2012). Motor neurons regulate myofiber type through
calcium/calcineurin/NFAT-MEF2 signaling (Schiaffino and Reggiani, 2011).

1.4
1.4.1

Muscle mass regulation

Sarcopenia

Sarcopenia, or loss of skeletal muscle mass with aging, is a universal phenomenon of human
society. Individuals over fifty begin to lose muscle mass at a rate of 1-2% per year, resulting in
losing up to 50% of muscle mass by the eighth decade (Buford et al., 2010; Walston, 2012).
Sarcopenia reduces individual’s physical activity and increases the risk of metabolic disease
(Cohen et al., 2015; Walston, 2012). It also increases household expenditures on healthcare; the
direct cost of sarcopenia-related care per year is estimated to be $18 billion in the United States
(Janssen et al., 2004). Although treatments for sarcopenia have enormous clinical and economic
benefits, there are few accepted approaches to prevent muscle loss (Cohen et al., 2015). The
development of effective therapies relies on our understanding of fundamental mechanisms
underlying muscle atrophy (White and LeBrasseur, 2014).
1.4.2

Signaling pathways regulating protein synthesis in skeletal muscle

Muscle atrophy occurs when the overall rates of protein degradation exceed the rates of protein
synthesis. The main signaling pathways control protein synthesis is the insulin-like growth factor
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1 (IGF1) – phosphoinositide 3-kinase (PI3K) –Akt/protein kinase B–mammalian target of
rapamycin (mTOR) pathway (Schiaffino et al., 2013). IGF1 binds to IGF1R to activate the p85
regulatory subunit of PI3K, which subsequently phosphorylates and activates Akt (Belfiore et al.,
2009). Akt then inhibits tuberous sclerosis complex 2 and activate the mammalian target of
rapamycin complex 1 (mTORC1) to promote protein synthesis (Wang and Proud, 2006).
Generally, mTORC1 promote protein synthesis through regulating initiation and elongation
factors, and the biogenesis of ribosomes, while the molecular mechanism is still not fully
understood (Wang and Proud, 2006).
Akt and mTOR are the hubs for additional signaling pathways that regulating muscle mass.
Stimulation of the β-adrenergic system with β-adrenoceptor agonists increases the
phosphorylation of Akt and thus induce muscle hypertrophy (Lynch and Ryall, 2008). Androgen
increases muscle mass through activating mTOR (Xu et al., 2006). In addition, Wnt7a binding to
Fzd7 directly activates Akt, thereby increasing muscle mass (von Maltzahn et al., 2011).
Overload-induced muscle hypertrophy is mediated by neuronal nitric oxide synthase (nNOS)
through activating transient receptor potential cation channel, subfamily V, member 1 (Trpv1).
The activated Trpv1 increases intracellular Ca2+ and subsequently activates mTOR (Ito et al.,
2013). Furthermore, mechanical stimulation activates mTOR signaling through phospholipase D
to induce muscle growth (Hornberger et al., 2006).
The studies on growth and differentiation factor-8 (GDF-8), or myostatin (Mstn) uncovers
another pathway regulating muscle mass (McPherron, Lawler, & Lee, 1997; White &
LeBrasseur, 2014). Mstn is an autocrine inhibitor of muscle growth and differentiation
(McPherron et al., 1997; Zimmers et al., 2002). Mstn binds activin type II receptors (ActRIIA
and ActRIIB), recruiting and activating activin-like kinase 4 (ALK4) or ALK5 to phosphorylate
Smad2 and Smad3, which form a transcriptional complex with Smad4 to trigger gene
transcription (White & LeBrasseur, 2014). Blocking it or its downstream elements (ActRIIA/B
or Smad2/3) causes muscle hypertrophy, highlighting the significance of the Mstn-ActRIIA/BSmad2/3 pathway in muscle mass regulation (Camporez et al., 2016; Lach-Trifilieff et al., 2014;
R. Sartori et al., 2009). However, downstream genes from the inhibition of this pathway are
largely unknown.
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Satellite cells also contribute to muscle hypertrophy through activating and fusing into existing
myofibers. However 90% satellite cell depletion does not influence overload-induced muscle
hypertrophy (Jackson et al., 2012; McCarthy et al., 2011). In addition, satellite cell dysfunction
does not inhibit Mstn deficiency-induced muscle hypertrophy (S. J. Lee et al., 2012). So the
significance of satellite cells in adult skeletal muscle hypertrophy may be limited.
1.4.3

Signaling pathways regulating protein degradation in skeletal muscle

Protein degradation is mainly processed in the ubiquitin-proteasome system. This system
includes two discrete and successive processes: conjugating substrate proteins with multiple
ubiquitin molecules; and the subsequent degradation of the tagged proteins by the 26S
proteasome (Lecker et al., 2006). The conjugation of ubiquitin to lysine residues of substrate
proteins requires three ATP-dependent enzymatic steps. E1 (Ub-activating enzyme) and E2 (Ubconjugating enzyme) prepare Ub for conjugation. E3 (Ub-ligating enzyme) binds to E2 and
substrate proteins to catalyzes the transfer of activated Ub (Lecker et al., 2006). E3 is the key
enzyme in the conjugation process. Two muscle-specific E3, muscle atrophy F box (Atrogin1/MAFbx) and muscle RING finger 1 (MuRF1), are key regulators of skeletal muscle atrophy
(Bodine et al., 2001). Atrogin-1 is an Fbox protein, which is a component of the Skp-CullinFbox protein (SCF) multi-protein E3, with a function of recruiting substrates to the SCF complex.
In contrast, MuRF1 is monomeric E3. Mice deficient in either Atrogin-1 or MuRF1 are resistant
to denervation-induced muscle atrophy (Bodine et al., 2001). The substrates of Atrogin-1 include
MyoD, eukaryotic translation initiation factor 3 subunit F (eIF3f) and calcineurin (Csibi et al.,
2010; Li et al., 2004; Tintignac et al., 2005). The substrates of MuRF1 includes troponin I,
myosin heavy chains, actin, myosin binding protein C and myosin light chains 1 and 2
(Schiaffino et al., 2013). Additional E3 and Fbox proteins responsible for muscle atrophy are
identified, like Trim32, TRAF6, Nedd4, Fbxo30 and Fbxo40 (Sartori et al., 2013; Schiaffino et
al., 2013; Shi et al., 2011).
The transcription of MuRF1 is activated by the cytokine TNFα through NFκB (Cai et al., 2004).
In addition, the transcriptional upregulation of Atrogin-1 and MuRF1 is controlled by Forkhead
box O (FoxO) class of transcription factors, a subfamily of the large group of forkhead
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transcription factors (Sandri et al., 2004). Mammalian cells contain four FoxO proteins, FoxO1,
FoxO3, FoxO4 and FoxO6 (Sanchez et al., 2014; Tran et al., 2003). FoxO1 or FoxO3 had been
shown to induce muscle atrophy (Kamei et al., 2004; Sandri et al., 2004). FoxO activity is
primarily regulated by posttranslational modifications (Sanchez et al., 2014). The
phosphorylation of FoxOs at Thr32, Ser253 and Ser315 by Akt induces the nuclear export of FoxOs
to the cytoplasm (Brunet et al., 1999). Additionally, PGC1α inhibits FoxO3-DNA binding
(Sandri et al., 2006).
FoxO is the signaling hub regulating muscle atrophy. Besides the activation of ubiquitinproteasome system, FoxO3 is also responsible for the induction of the autophagy-lysosome
system, which is another major system of protein breakdown in the skeletal muscle (Mammucari
et al., 2007). The autophagy-lysosome system utilizes lysosomes to degrade cytoplasmic material
and organelles in response to nutrient stress. Three types of autophagy are described, according
to the delivery route of the cytoplasmic material to the lysosomal lumen: First, the
macroautophagy, in which the cytoplasmic material is wrapped inside a spherical structure with
double layer membranes, the autophagosome, and fused with lysosome for protein degradation;
second, the microautophagy, in which the cytoplasmic material is trapped in the lysosome trough
membrane invagination; and third, the chaperone-mediated autophagy (CMA), in which the
cytoplasmic material with CMA-targeting motif is recognized by heat shock cognate protein of
70 kDa (Hsc70) and delivered to lysosome lumen through lysosome-associated membrane
protein type 2A (Lamp2a) (Eskelinen & Saftig, 2009).
The key step of macroautophagy is the formation of autophagosome. Autophagosome is
originated from an isolation membrane, or the phagophore. Phagophore will elongate and
meanwhile engulf cytoplasmic material, and finally fuse its edges to form the autophagosome
(Rubinsztein et al., 2011). The origin of phagophore is under debate, while evidences show that
ER and mitochondria are the sources of the phagophore (Hailey et al., 2010; Hayashi-Nishino et
al., 2009). In addition, the delivery of membrane from the Golgi apparatus and the plasma
membrane is involved in the formation of autophagosome (Taylor et al., 2012; van der Vaart et
al., 2010; Yen et al., 2010).
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Autophagosome biogenesis is mediated by autophagy-related genes (Atgs) and several protein
complexes (Bento et al., 2016). The machinery of phagophore formation requires two
macromolecular complexes: the Ulk1 complex (Ulk1, Atg13, Atg101 and FIP200) and the class
III PI3K complex I (Vps34, Beclin1, Vps15, and Atg14). Ulk1 is activated in response to
nutrient deprivation, and activated Ulk1 kinase recruits Vps34 (PI3K complex) to the
phagophore initiation site (Itakura & Mizushima, 2010). At the sites of phagophore initiation, the
PI3K complex produces phosphatidylinositol 3-phosphate (PI3P), which favors bending of the
membrane, relating to phagophore sculpting (Bento et al., 2016). In addition, PI3P recruits PI3Pbinding proteins of the WIPI family, including WIPI2 to bind with the Atg16L1-Atg5/12
complex, which is formed in an ubiquitination-like reaction, where Atg12 (an ubiquitin-like
protein) is conjugated to Atg5 by Atg7 (an E1-like protein) and Atg10 (an E2-like protein), and
the Atg5-Atg12 binds with Atg16L1. The Atg16L1-Atg5/12 complex associates with the
elongation of membranes, helps to define the location of autophagosome formation (Bento et al.,
2016).
The Atg16L1-Atg5/12 complex also acts as an E3-like enzyme to catalyze the conjugation of
Atg8 to the lipid phosphatidylethanolamine (PE) in a second ubiquitin-like reaction through Atg7
(E1-like) and Atg3 (E2-like) (Sakoh-Nakatogawa et al., 2013). There are two subfamilies of
Atg8 orthologs: LC3 and GATE-16/GABARAP (Weidberg et al., 2010). LC3s are involved in
elongation of the phagophore membrane whereas the GABARAP/GATE-16 subfamily is
essential for a later stage in autophagosome maturation (Weidberg et al., 2010). The process of
autophagosome closure may be regulated by Atg2 (Velikkakath, Nishimura, Oita, Ishihara, &
Mizushima, 2012). The fusion of autophagosome and lysosome is mediated by the SNARE
proteins VAMP8 and Vti1b (Furuta, Fujita, Noda, Yoshimori, & Amano, 2010).
Macroautophagy contributes to muscle mass loss in stressful condition, such as denervation,
fasting or oxidative stress (Dobrowolny et al., 2008; Furuno et al., 1990; Pietri-Rouxel et al.,
2010). Macroautophagy not only recycles cytoplasmic material to compensate for nutrient
deprivation but also selectively degrade organelles to maintain their number and quality. In this
case, basal macroautophagy is required for muscle homeostasis. For example, mitophagy is a
selective macroautophagy for mitochondria degradation. It is mediated by the kinase PTEN-
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induced putative kinase protein 1 (PINK1) and the E3 ubiquitin ligase parkin in mammals (Youle
and Narendra, 2011). When mitochondria is damaged, PINK1 accumulates and recruits parkin to
mitochondria, where parkin promotes mitophagy through ubiquitylation of outer mitochondrial
membrane proteins that are recognized by the ubiquitin binding adaptor p62 (Youle and
Narendra, 2011). Ubiquitin polymers may directly or indirectly bind with LC3 via p62, and
recruit the autophagosome to mitochondria (Youle and Narendra, 2011). Impairment of basal
mitophagy causes the accumulation of damaged mitochondria, leading to myofiber degeneration
(Grumati et al., 2010).
The roles of microautophagy and CMA in skeletal muscle are largely unknown. Microautophagy
is found to mediate glycogen uptake into lysosomes (Raben et al., 2008). CMA mediates the
degradation of Mef2A and Mef2D (Q. Yang et al., 2009; L. Zhang et al., 2014). Mef2 is
important for slow myofiber formation (Potthoff, Wu, et al., 2007), so CMA may be involved in
the myofiber type regulation.

1.5

Post-translational modification of proteins

Cellular signal transduction is transmitted by protein-protein interactions through posttranslational modifications (PTMs) of proteins. More than 200 protein PTMs have been
described, including phosphorylation, ubiquitination, sumoylation, acetylation and methylation
(Humphrey et al., 2015).
Phosphorylation is the most abundant and best-characterized PTM. Phosphorylation is a process
that a phosphate is transferred from ATP to serine, threonine, or tyrosine residual of a protein.
The phosphorylation process is catalyzed by kinases. The counterpart of kinase, phosphatase
catalyzes the removal of phosphate from a phosphorylated protein substrate. Kinase and
phosphatase together regulate the irreversible protein phosphorylation which is a molecular
switch mechanism (Humphrey et al., 2015). In general, the irreversible protein phosphorylation
mediates cellular signal transduction through regulating enzymatic activity, protein turnover,
protein-protein interactions, protein conformation, protein localization, and crosstalk with other
PTM (Humphrey et al., 2015). The MAP kinase p38 phosphorylates Ser 387, Thr293 and Thr300 of
Mef2C and Thr312 and Thr300 of Mef2A, enhancing their transcriptional activity (Han et al., 1997;
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Zhao et al., 1999). MyoD is phosphorylated by cyclin-dependent kinase (CDK) at Ser 200 and the
phosphorylation increases the degradation of MyoD (Song et al., 1998). In contrast, the
phosphorylation of MyoD at Tyr165 by mitogen-activated protein kinase kinase-1
(MAP2K1/MEK1) protects MyoD from the ubiquitin proteasome-mediated degradation (Jo et al.,
2011).
Ubiquitination plays an important role in protein degradation through the ubiquitin-proteasome
system (Lecker et al., 2006). Atrogin-1 catalyzes the conjugation of ubiquitin to MyoD and
promotes the degradation of MyoD (Tintignac et al., 2005). Notably, ubiquitination does not
definitely lead to the degradation of proteins. In some cases the ubiquitin-mediated destruction of
protein is required for protein maturation and activation (Geng, Wenzel, & Tansey, 2012).
Ubiquitin also has non-proteolytic functions in regulating transcriptional regulators (Geng et al.,
2012). Monoubiquitination does not change the half-life of FoxO4, but results in its
relocalization to the nucleus and thus increases its transcriptional activity (van der Horst et al.,
2006).
Sumoylation and ubiquitination occur through a similar E1/E2/E3 enzyme cascade (CubenasPotts and Matunis, 2013; Lecker et al., 2006), but the small ubiquitin-related modifier (SUMO)
is not used to tag proteins for degradation. Sumoylation mainly function in regulating chromatin
structure and gene transcription (Cubenas-Potts and Matunis, 2013). Sumoylation represses gene
expression through different mechanisms, including promoting DNA methylation through
DNMT1 activation (Lee and Muller, 2009), facilitating assembly of repressive complexes
(Uchimura et al., 2006), inhibiting the activities of transcription factors and promoting the
assembly of repressive polycomb group bodies (Shalizi et al., 2006; Zhang et al., 2004). In turn,
sumoylation also promotes gene activation through DNA demethylation mediated by the SUMOtargeted ubiquitin E3 ligase (Hu et al., 2010), assembly of activating complexes (Gomez-del
Arco et al., 2005), and the recruitment of RNA polymerase II (Rosonina et al., 2010).
Sumoylation of Mef2A at Lys403 inhibits its transcriptional activity (Shalizi et al., 2006).
Sumoylation of Bhlhe40 at Lys159 and Lys279 enhances its ability as a transcription repressor
(Kunz et al., 2016).
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Protein acetylation is a process that an acetyl group is transferred from acetyl coenzyme A (AcCoA) to a lysine residue of a protein. Acetylated lysine residues were first discovered in histones
(Allfrey & Mirsky, 1964). The acetylation of histones is extensively documented (Drazic,
Myklebust, Ree, & Arnesen, 2016). Acetylation negates the positive charge of lysine and thus
reduces the affinity of histones for DNA. In this case, histone acetylation releases DNA from the
nucleosome and increases gene expression (Eberharter & Becker, 2002). Protein acetylation is
not exclusively limited to histones (Glozak, Sengupta, Zhang, & Seto, 2005). FoxO1 is
acetylated by histone acetyltransferase cAMP-response element-binding protein (CREB)-binding
protein (CBP) at Lys242, Lys245, and Lys262 (Matsuzaki et al., 2005). The acetylation
decreases the binding of FoxO1 to DNA and represses its transcriptional activity. Acetylation
does not necessarily decrease activity of transcription factors. Acetylation maintains the
transcriptional activity of Mef2C and p53 (Glozak et al., 2005; Ma, Chan, Zhu, & Wu, 2005).

1.6
1.6.1

Proteins methylation

Classification of methyltransferases

Methylation is mediated by methyltransferase which transfer a methyl group (CH3) from a donor,
generally S-adenosyl-L-methionine (AdoMet) to various substrates, including DNA, RNA,
protein and small molecules (Copeland, Solomon, & Richon, 2009). There are five structurally
distinct families of AdoMet-dependent methyltransferases (Schubert, Blumenthal, & Cheng,
2003): seven-β-strand methyltransferases (class I), cobalamin dependent methionine synthase
(class

II),

precorrin-4

C11-methyltransferase

(class

III),

SPOUT

family

of

RNA

methyltransferase (class IV) and SET domain-containing protein lysine methyltransferases (class
V). Most of the methyltransferases are belong to class I, class IV and class V. Class I family
contains a wide range of methyltransferases with different substrate residuals, including DNA
methyltransferases (Okano, Bell, Haber, & Li, 1999), microRNA methyltransferase, protein
arginine methyltransferases (Y. Yang & Bedford, 2013), and disruptor of telomeric silencing-1
(DOT1) lysine methyltransferase (Feng et al., 2002). Class IV family contains only RNA
methyltransferases expect one protein arginine methyltransferase (Young et al., 2012). Class V
methyltransferases are protein lysine methyltransferases (Dillon, Zhang, Trievel, & Cheng, 2005).
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1.6.2

Histone methylation

Protein methylation occurs most common at lysine and arginine residues (Clarke, 2013),
although there are other residues for methylation including histidine (Webb et al., 2010),
glutamate (Sprung et al., 2008), glutamine (Klotz et al., 1990; Tessarz et al., 2014), asparagine
(Klotz et al., 1990), D-aspartate (Sprung et al., 2008), cysteine (Zhang et al., 2011), N-terminal
(Tooley et al., 2010), and C-terminal residues (Stephenson and Clarke, 1990). Methylation alters
the hydrophobic, charge distribution and steric properties of a residue, leading to changes in
protein stability, protein-protein interactions and protein-DNA interactions (Hamamoto et al.,
2015). It has been pervasively characterized that histone methylation regulates the chromatin
structure and thus modulates gene expression (Black et al., 2012).
There are four core histones H2A, H2B, H3 and H4, which are wrapped by 146 bp DNA to form
the nucleosome. The nucleosomes are further packaged into 30-nm solenoid-like chromatin fiber
with six nucleosomes per turn with the presence of histone H1 (Hayes and Hansen, 2001).
During gene transcription, the 30-nm fiber is required to unfold to allow the binding of
transcription factor to DNA. Each core histone is composed of two tails. The tail is dispensable
for the formation of nucleosome, but is required for packaging of nucleosome to high order
chromatin structure (Pepenella et al., 2014). PTM of the tail is involved in unfolding of the 30nm fiber to a released 11-nm fiber (beads on a string). Thus, these PTMs form the histone code
for regulating chromatin structure and gene expression (Jenuwein and Allis, 2001).
Histone methylation is an important component of the histone code. Histones are methylated on
lysine and arginine residuals. Lysine methylation has mono-, di- or trimethylated form. Different
from lysine methylation, arginine methylation only has mono- or dimethylated form, and the
dimethylation has symmetric of asymmetric configurations (Di Lorenzo and Bedford, 2011).
Histone lysine methylation is correlated with transcription activation or transcription silencing,
depending on the sites of methylation (Zhang and Reinberg, 2001). Generally, methylation on
histone H3 lysine 4 (H3K4), H3K36, and H3K79 is related to transcriptional activation (Zhang et
al., 2012). In contrast di- and tri-methylation on H3K9, H3K27, and H4K20 are linked to
transcriptional repression (Zhang et al., 2012). The role of histone arginine methylation on
transcription is determined by the sites and also the configuration of methylation (Litt et al., 2009;
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Yang and Bedford, 2013). For example, asymmetric dimethylation of H4R3 and H3R8 are
associated with transcriptional activation, whereas symmetric dimethylation of H4R3 and H3R8
are associated with transcriptional repression (Yang and Bedford, 2013).
Methylated lysine and arginine could serves as binding sites for molecules involved in
transcriptional activation or repression. Methylated H3K4 interacts with Chd1 and recruits a
histone acetyltransferase (HAT) complex to activate gene transcription (Pray-Grant, Daniel,
Schieltz, Yates, & Grant, 2005). In addition, dimethylated H3K4 interacts with WDR5 and
recruits the mixed-lineage leukemia (MLL) methyltransferase complex to convert dimethylated
H3K4 to trimethylated H3K4 (Wysocka et al., 2005). In contrast, symmetric dimethylated H4R3
is a docking site for the DNA methyltransferase DNMT3A, causing DNA methylation and gene
silencing (Q. Zhao et al., 2009).
Methylation could also influence gene transcription through the cross-talk between lysine and
arginine methylation, such as the methylated H3R2 prevents the H3K4 trimethylation and the
recruitment of WDR5 (Hyllus et al., 2007).
1.6.3

Non-histone methylation

Compared with histone methylation, non-histone protein methylation is a relatively nascent area
of research. Although it is believed that non-histone methylations is an important regulator of
biological process (Biggar and Li, 2015), there is still lack of studies illustrating the biological
significance of non-histone methylation.
Current knowledge indicates that methylation could regulate protein functions through the
crosstalk with other PTMs (Biggar & Li, 2015; X. Zhang et al., 2012). The tumor suppressor,
p53 is the first non-histone protein identified to be methylated at Lys372 (Chuikov et al., 2004).
The methylation at Lys372 stimulates acetylation of p53 at Lys373/382 (Ivanov et al., 2007).
Acetylated Lys373/382 then increases the transcriptional activity of p53 (Luo et al., 2004;
Mujtaba et al., 2004). Notably, the Lys382 could also be monomethylated by a SET domaincontaining protein lysine methyltransferase SET8 (X. Shi et al., 2007). The methylation directly
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blocks the Lys382 acetylation and thus inhibits the transcriptional activity of p53 (X. Shi et al.,
2007).
Arginine methylation influences PTMs as well. FoxO1 is phosphorylated by Akt at Ser 253,
leading to increased cytoplasmic retention of FoxO1 (Brunet et al., 1999). When FoxO1 is
methylated at Arg248 and Arg250 by protein arginine N-methyltransferase 1 (PRMT1), the
phosphorylation at Ser253 will be blocked by the methylation. In turn, methylated FoxO1 has
increased nucleus localization and enhanced transcriptional activity (Yamagata et al., 2008).
Besides the methylation-acetylation crosstalk and the methylation-phosphorylation crosstalk,
there is methylation-methylation crosstalk. A lysine methyltransferase, Smyd2 could methylate
p53 at Lys372 (Huang et al., 2006). The Lys372 methylation is negatively correlated with Lys370
methylation, as methylated Lys370 interrupts the interaction between p53 and Smyd2 (Huang et
al., 2006).
The example above also indicates that methylation could regulate protein-protein interactions.
Another example is the methylation of p53 at Lys372 by Set7/9 is required for the binding of a
MYST family acetyltransferase Tip60 to p53 and for the subsequent acetylation of p53 (Kurash
et al., 2008). In addition, SMYD3-mediated methylation of MAP3K2 at Lys 260 blocks its
interaction with the PP2A phosphatase complex (Mazur et al., 2014). Through regulating PTMs
and protein-protein interactions, methylation has been shown to regulate cell signaling pathways,
including RAS-RAF signaling, EGFR signaling, BMP signaling, WNT signaling, and JAKSTAT signaling (Biggar and Li, 2015).

1.7

Methyltransferase like 21 proteins

Protein lysine methyltransferases (PKMTs) almost exclusively contain the SET domain. For
many years, the only known seven-β-strand (7BS) PKMT is Dot1 (Feng et al., 2002). Until
recently, a group of human 7BS PKMTs is characterized (Cloutier et al., 2013; Falnes et al.,
2016). The discovery of this PKMT group was originated from an analysis of a 7BS
methyltransferase METTL22 which was identified to share distant homology with the known
7BS protein arginine methyltransferases (PRMTs) (Cloutier et al., 2013). Subsequent local
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alignment searches using METTL22 as seed uncovered 10 putative methyltransferases forming a
group sharing distant homology with PRMTs (Cloutier et al., 2013). These 10 putative
methyltransferases constitute the human members of the so-called methyltransferase family 16
(MTF16). The substrate of 7 of these human enzymes has now been established: CAMKMT
methylates calmodulin at Lys115 (Magnani et al., 2010), METTL22 methylates the DNA/RNA
binding protein Kin17/KIN at Lys135 (Cloutier et al., 2013; Cloutier et al., 2014), FAM86A
methylates eukaryotic elongation factor 2 (eEF2) at Lys525 (Davydova et al., 2014), METTL20
(ETFβ-KMT) methylates ETFβ at Lys200/203 (Malecki et al., 2015), METTL21A (HSPA-KMT)
methylates several HSPA (Hsp70) proteins (Jakobsson et al., 2013), METTL21B methylates
eEF1A at Lys165 (Hamey et al., 2017; Malecki et al., 2017), and METTL21D (VCP-KMT)
methylates the ATP-dependent chaperone VCP at Lys315 (Cloutier et al., 2013; Kernstock et al.,
2012). The substrates of the other three human MTF16 members, METTL18, METTL21C and
METTL23, have not been verified.
Among the proteins of MTF16,

METTL21A-D are grouped together in the phylogenetic

analysis (Cloutier et al., 2013). These four methyltransferases constitute the human
methyltransferase-like 21 (METTL21) family. The substrates of METTL21A-B and D have been
established (Cloutier et al., 2013; Hamey et al., 2017; Jakobsson et al., 2013; Kernstock et al.,
2012; Malecki et al., 2017). Although the substrate of METTL21C is not identified, it has been
shown that METTL21C interacts and potentially methylates molecular chaperones (Cloutier et
al., 2013). In addition, METTL21C is highly expressed in skeletal muscles (Huang et al., 2014).
Intriguingly, a genome-wide association study (GWAS) identified METTL21C as a pleiotropic
gene for both skeletal muscle and bone (Huang et al., 2014). And knockdown of Mettl21c
impairs myogenesis of C2C12 myoblasts (Huang et al., 2014). However, there is no study to
evaluate the role of METTL21C/Mettl21c in vivo. Interestingly, mouse Mettl21 family contains
one more member, the Mettl21e. The counterpart of Mettl21e in human is denoted as a unitary
pseudogene (Zhang et al., 2010). Human METTL21E was possibly inactivated by a splicejunction mutation (AG to TA) located at the acceptor-splice site of its second intron. The mouse
Mettl21e encodes 244 amino acid residues with a calculated molecular mass of 28.1 kDa and an
isoelectric point (pI) of 6.08. I analyzed microarray and RNA-seq data comparing gene
expression in the skeletal muscles of control and Mstn knockout (KO) mice (Caetano-Anolles et
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al., 2015; Welle et al., 2009b), which exhibit robust myofiber hypertrophy and increased
abundance of IIb myofibers. This analysis led to the identification of Mettl21e gene, which was
among the top up-regulated genes in Mstn KO mice. Intriguingly, the expression of Mettl21e is
also increased in the Callipyge sheep model of muscle hypertrophy (Fleming-Waddell et al.,
2009), suggesting a conserved link between Mettl21e and muscle hypertrophy.

1.8

Aim of this thesis

In this study, I aim to elucidate the role of Mettl21c and Mettl21e in skeletal muscles. For
Mettl21c, I will use the Mettl21cLacZ knockin/knockout mouse model to investigate the
expression and function of Mettl21c in vivo. Meanwhile, I will use loss-of-function and gain-offunction approaches combined with affinity purified-mass spectrometry to find out the substrate
of Mettl21c. For Mettl21e, I will use gain-of-function and loss-of-function assays in cell culture
and in mice models to investigate the in vivo function of Mettl21e. Then I will use mass
spectrometry to identify potential substrate of Mettl21e. The studies of Mettl21c and Mettl21e
together elucidate the role of non-histone methyltransferases in regulating myofiber homeostasis
and identity.
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CHAPTER 2.

METHODS AND MATERIALS

2.1

Mice model

Constitutive Mstn KO mice (Mstn-/-) were generated by Dr. S. E. Jin-Lee, Johns Hopkins
University (McPherron et al., 1997). Heterozygous Mstn+/− mice were bred to generate Mstn−/−
and WT (Mstn+/+) littermates. MyIIA-RFP mice were generated by Dr. Joshua R Sanes, Harvard
University (Chakkalakal et al., 2012). The Mettl21c LacZ/+ mice (stock#025271) were from
Jackson lab. The Mettl21eOE mice were generated in Transgenic Mouse Core Facility, Purdue
University. The TALEN-mediated Mettl21e knockout mice were produced by Beijing View
Solid Biotechnology, China. Without special mentioning, we used 2-month old mice for
experiments. All procedures involving the use of animals were performed in accordance with the
guidelines presented by Purdue University’s Animal Care and Use Committee.
2.1.1

Generation of muscle specific Mettl21eOE mice

The coding sequence for the Mettl21e was cloned from myoblasts and ligated to the PacI site of
the pCCLMCKII vector (a gift by Dr. Ashok Kumar, University of Louisville). The orientation
of cDNA was confirmed by DNA sequencing. The expression cassette containing the 3.5kb
MCK promoter, Mettl21e cDNA and polyA tail was excised using SwaI restriction enzyme and
purified using Gel extraction kit (D2500-02, Omega bio-tek). Transgenic mice were generated by
pronuclear injection using standard methods. Founder mice were screened for the presence of
transgene

by

PCR

primers

(5’-GGCTAGTCACACCCTGTAGG

-3’

and

5’-

CTAGGCACTCCGATTTTT-3’) using genomic DNA from ears. Founder mice were bred with
WT mice to generate Mettl21eOE and WT littermates that were used in this study.
2.1.2

Generation of TALEN-mediated Mettl21e knockout mice

The TALEN plasmid pCS5-eTALEN-T was designed to induce Mettl21e frameshift mutation.
TALEN-left targets the sequence (5’-GGTCGCAGAGATCATGG -3’) of the sense strand; and
TALEN-right targets the sequence (5’-AGTCGTTATCAGAGTTG-3’) of the antisense strand.
Mutated mice were generated by pronuclear injection using standard methods. Founder mice
were screened for the presence of mutation by sequencing the PCR products amplified by the
primers: Mettl21e-sens (5’-ATGGACCTCACAGTAACTCACAT-3’) and Mettl21e-anti (5’-GC
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TTGCCACAATGGAGACAAG-3’). Mutant mice were mated with wild-type C57BL/6 mice to
obtain heterozygous Mettl21eHET mice. Mettl21eHET mice were then mated at least 3 generations
to obtain Mettl21eKO and WT mice.

2.2

Primary myoblasts isolation, culture and differentiation

Primary myoblasts were isolated from 5-week old WT female mice. The hind limb skeletal
muscles were minced and digested in type I collagenase and dispase B mixture (Roche Applied
Science). The digestion was stopped with F-10 Ham’s medium containing 17% fetal bovine
serum (FBS), and the cells were filtered from debris, centrifuged and cultured in growth media
(F-10 Ham’s media supplemented with 17% FBS, 4 ng ml−1 basic fibroblast growth factor and 1%
penicillin-streptomycin) on uncoated dishes for three days when 5 ml growth media were added
each day. Then the supernatant was collected, centrifuged and trypsinized with 0.25% trypsin.
After washing off the trypsin, primary myoblasts were seeded on collagen-coated dishes, and the
growth medium was changed every two days. Myoblasts were induced to differentiate on
matrigel-coated dishes and cultured in differentiation media (DMEM supplemented with 2%
horse serum and 1% penicillin-streptomycin). Differentiation media was replaced everyday.
Primary myoblasts were cultured in normal humidified tissue culture incubators with 5% CO 2.
To inhibit Mstn signaling, cells were treated with 200 ng ml−1 Mstn antibody (kindly provided
by Dr. Yong-Soo Kim, University of Hawaii) (M. Wang, Yu, Kim, Bidwell, & Kuang, 2012), or
200 ng ml−1 follistatin (SRP3045, Sigma). To inhibit proteasome activity, differentiated
myoblasts were treated with 25 nM bortezomib (B-1408, LC laboratories).

2.3

Skeletal muscle cryosection

After dissection, skeletal muscles (tibialis anterior, soleus, and extensor digitorum longus) were
embedded in embedding molds (SPI Supplies) with minimum amount of Tissue-Tek O.C.T.
compound possible to cover the muscles. A cold-resistant beaker of 2-methylbutane was placed
into a slurry of dry ice, which allows fast cooling to -78 °C. When the correct temperature is
attained, no bubble will appear after putting a piece of dry ice into the 2-methylbutane. The
embedded muscles were frozen by placing the embedding molds with muscles into the cooled 2methylbutane for 5 min. Then the muscle samples were transferred to a -80 °C freezer for storage.
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Before cryosectioning, the cryostat with the blade was pre-cooled to -22 ± 2 °C. Samples were
placed in cryostat for at least 20 min for thermal equilibration, and then were attached on round
metallic holders of the cryostat with Tissue-Tek O.C.T. Sample sections were cut at 10-µm-thick
and were collected by positive charged microscope slides which were then stored in a slide box
at a -80 °C freezer. These slides were processed further for immunostaining and X-gal staining.

2.4

Immunostaining

Muscle sections, myoblasts or myotubes were fixed with 4% paraformaldehyde, and then were
blocked with blocking buffer (5% goat serum, 2% BSA, 0.2% triton X-100, and 0.1% sodium
azide in PBS) for at least 1 h. Then the samples were incubated with primary antibodies (1:200 in
blocking buffer) [MF20, Myh7 (BA-D5), Myh2 (2F7) and Myh4 (10F5) were from
Developmental Studies Hybridoma Bank, Dystrophin (ab15277), Ki67 (ab16667) and
NOQ/Myh7 (ab11083) was from Abcam and FLAG (F1804) was from Sigma] overnight. After
washing with PBS, the samples were incubated with respective secondary antibodies (1:1000 in
PBS) [goat anti-Mouse IgG1, Alexa Fluor 568 (A-21124), goat anti-mouse IgG1, Alexa Fluor
488 (A-21121), goat anti-Mouse IgG2b, Alexa Fluor 568 (A-21144), goat anti-Mouse IgM,
Alexa Fluor 488 (A-21042), goat anti-rabbit IgG (H+L), and Alexa Fluor 647 (A-21245) were
from Thermo Fisher Scientific] and DAPI for 45 min at room temperature. Fluorescent images
were captured using a Leica DM 6000B fluorescent microscope. To quantify the signals of
control and treatment samples, images were captured with the same exposure time. The positive
signal should have a reasonable shape (e.g. myotube-like shape for the staining of Myh7). For
muscle samples, five different areas were captured for each section, and four sections were
analyzed for each sample. For culture myoblasts and myotubes, five different areas were
captured for each sample. Then, the mean of the 20 numbers or 5 numbers was calculated to be
the average quantity of a sample, which was used for the statistical analysis.

2.5

X-gal staining

Myoblasts and tissue slides were fixed for 5 min. Tissues and embryos were fixed for 30 min.
Then cells (and tissues) were washed with washing buffer (0.1 M phosphate buffer, pH 7.3, 2
mM MgCl2, and 0.02% NP40) for at least 3 times. Then cells (and tissues) were stained with
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staining buffer (washing buffer containing 1 mg ml−1 X-gal in dimethyl formamid, 2.12 mg ml−1
potassium ferrocyanide and 1.64 mg ml−1 potassium ferricyanide) overnight at 37 °C. After
staining, pour off the staining buffer and replace with wash buffer. Images were captured with a
14.0 MP digital microscope camera which is attached via a c-mount to the side port of a Leica
DMI 6000B microscope.

2.6

Single myofiber isolation

Single myofibers were isolated from EDL or SOL muscles of MyIIA-RFP mice (Pasut et al.,
2013). EDL and SOL muscles were removed carefully and digested with 2 mg ml −1 collagenase
type 1 (CLS-1, Worthington) in Dulbecco’s Modified Eagle’s Medium (DMEM, Sigma) for
about 1 h at 37 °C. Digestion was stopped by carefully transferring EDL or SOL muscles to a
horse serum-coated Petri dish (60-mm) with DMEM. Myofibers were released by gently flushing
muscles with large bore glass pipette. Released single myofiber was transferred to a 0.2 ml PCR
tube. RNA of a single myofiber was extracted using a PicoPure RNA isolation kit (KIT0204,
ThermoFisher Scientific) according to the manufacturer's protocol.

2.7

RNA extraction and Real-time qPCR

Total RNA of muscles or myoblasts was extracted using Trizol Reagent. RNA was treated with
RNase-free DNase I to remove genomic DNA. The purity and concentration of total RNA were
measured by Nanodrop 3000 (Thermo Fisher). Random primers and Moloney murine leukemia
virus reverse transcriptase were used to convert RNA into cDNA. Real-time PCR was performed
using Roche Lightcycler 480 PCR System with SYBR Green Master Mix. Primers used were
listed in Table 2.1. Ct value of 18S rRNA was used as internal control and 2−ΔΔCT method was
used to analyze the relative mRNA expression of various genes.

2.8

Chromatin immunoprecipitation

Primary myoblasts were induced to differentiate with differentiation media for 3 days.
Differentiated myoblasts were cross-linked with 1% formaldehyde in differentiation media for
10 min at room temperature (RT) followed by the addition of 125 mM glycine for 5 min at RT,
after which cells were scraped into SDS lysis buffer (50mM Tris (pH 8.1), 10mM EDTA and 1%
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SDS). The cells were further sonicated and diluted for immunoprecipitation with the MyoD
antibody (M318, Santa Cruz) or the

IgG (sc-2027, Santa

Cruz) antibody. The

immunoprecipitates were eluted and reverse cross-linked overnight at 65°C. DNA fragments
were purified using the Cycle Pure kit (Omega, GA), and the Mettl21e promoter region was
amplified by real-time PCR (Table 2.1).

2.9

Protein extraction and western blots analysis

Muscle samples and cultured myoblasts were washed with PBS and homogenized with
radioimmune precipitation assay buffer (50 mM Tris-HCl (pH 8.0), 150 mM NaCl, 1% NP-40,
0.5% sodium deoxycholate, and 0.1% SDS). Protein concentrations were determined using
Pierce BCA Protein Assay Reagent (Pierce Biotechnology). Proteins (100 ug) were separated by
10% SDS-PAGE, electrotransferred onto PVDF membrane (Millipore Corporation, Billerica,
MA), and incubated with specific primary antibodies. MEF2A (B-4), MEF2D (H-11), GFP (B-2),
MyoD (M318), Myogenin (F5D) and GAPDH (6C5) antibodies (1:1000 in 5% w/v nonfat dry
milk) were from Santa Cruz, MF20 (1:100 in 5% w/v nonfat dry milk) was from Developmental
Studies Hybridoma Bank, and Hspa8/Hsc70 (ab2788), NOQ/Myh7 (ab11083) and Lamp2a
(ab18528) antibodies (1:1000 in 5% w/v nonfat dry milk) were from Abcam. Immunodetection
was performed using enhanced chemiluminescence (ECL) Western blotting substrate (Pierce
Biotechnology) and detected with FluoChem R imaging system (ProteinSimple).

2.10 Myonuclei and sarcoplasm protein preparation
SOL muscle were homogenized in the cell lysis buffer (10 mM HEPES, pH 7.5, 10 mM KCl, 0.1
mM EDTA, 1 mM DTT, 0.5% NP‐40, 0.5 mM PMSF and 1x protease inhibitor cocktail) and
allowed to swell on ice for 15‐20 min with intermittent mixing. Tubes were vortexed to disrupt
cell membranes and then centrifuged at 12,000 g at 4°C for 10 min. The supernatant is the
sarcoplasm extract. The pelleted nuclei were washed twice with the cell lysis buffer and
resuspended in the nuclear extraction buffer (20 mM HEPES, pH 7.5, 400 mM NaCl, 1 mM
EDTA, 1 mM DTT, 1 mM PMSF and 1x protease inhibitor cocktail) and incubated in ice for 30
min. Myonuclei extract was collected by centrifugation at 12,000 g for 15 min at 4°C.
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2.11 Adenovirus generation
The adenoviruses with Mettl21e shRNAs, Mstn, Mettl21e, Mettl21e-FLAG, Hspa8, Mettl21c or
Mettl21c-FLAG were generated using the AdEasy system. We subcloned the U6-shRNA
cassettes

from

pLKO.1-U6-shRNA

plasmids

(Sigma,

Sh1:

TRCN0000176763;

Sh2:

TRCN0000177496; Sh3: TRCN0000177877; Sh4: TRCN0000176682) with primers (pLKO.1f/r, Table 2.1). Mstn ORF, Mettl21e ORF, Mettl21e-FLAG ORF, Hspa8 ORF, Mettl21c ORF
and Mettl21c-FLAG ORF were cloned with primers (Mstn-f/r for Mstn; Mettl21e-f /r for
Mettl21e; Mettl21e-f/Mettl21e-FLAG-r for Mettl21e-FLAG, Hspa8-f/r for Hspa8; Mettl21c-f /r
for Mettl21c; Mettl21c-f/Mettl21c-FLAG-r for Mettl21c-FLAG Table 2.1). These cloned DNA
sequences were inserted into pAdTrack-CMV plasmid (The cloned Mettl21e-FLAG ORF,
Mettl21c-FLAG or Mettl21c ORF was also inserted into pcDNA3.1), and then were digested by
PmeI and transfected the DH5a competent cell with pAdEasy-1. The positive recombinant
plasmid was detected by PacI digestion. Then, HEK293A cells (60%-70% confluent) in 10 cm
culture dishes was transfected with the 4 μg PacI digested recombinant plasmid using
Lipofectamine 2000 (Life Technologies) according to manufacturer’s protocol. The HEK293A
cells had been checked through a Leica DM 6000B fluorescent microscope to avoid
contamination of adenovirus (GFP+). After 14 days incubation, the recombinant adenovirus was
released by four freeze–thaw–vortex cycles. Two more round infections were adapted to amplify
the recombinant virus and the titers were determined by the expression of GFP.

2.12 Mettl21e overexpression cell line selection
The Mettl21e ORF was cloned with primers (Mettl21e-f/Mettl21e-r, Table 2.1) and inserted into
a pQCXIP plasmid. C2C12 cells were electroporated with the pQCXIP-Mettl21e or pQCXIP (1
ug 106 cell-1). Two days after electroporation, puromycin (1 µg/ml) was added to the culture
media. Seven to ten days after puromycin selection, single cell clones were detached by 0.25x
trypsin and transferred to 12 well plates. When the cell confluency was over 70%, cells were
passaged and analyzed for Mettl21e expression.
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2.13 Mass spectrometry analysis
2.13.1 Identification of Mettl21e using mass spectrometry
Due to the lack of Mettl21e antibody, I used mass spectrometry to identify Mettl21e in TA
muscles. TA proteins were separated with 10% SDS-PAGE gel. To avoid high abundance
proteins in TA muscles, coomassie stained protein bands with 25kDa-35kDa (containing the
position of Mettl21e ~28kDa) were excised with a razor and cut into 1 mm pieces. Gel pieces
were destained with successive washes of 50% ACN in water, 100% ACN, 50 mM TMAB, 50%
ACN in 50 mM TMAB, and 100% ACN. Destained gel pieces were briefly dried and incubated
with 10 mM DTT in 50 mM TMAB for 1 hr at 56°C to reduce protein disulfide bonds. Reduced
cysteines were then alkylated with 55 mM IAA in 50 mM TMAB for 1 hr at room temperature in
the dark. The solution was removed, and the gel pieces were washed with 50 mM TMAB
followed by ACN. Dehydrated gel pieces were swelled at 4°C in a buffer of 50 mM TMAB
containing 500 ng proteomics grade trypsin. After 30 min, the samples were transferred to 37°C
and allowed to incubate overnight. On the next day, the supernatant was collected. Additional
peptides were recovered from the gel pieces with successive elutions of 50 mM TMAB, ACN,
and 0.5% TFA. The eluted peptides were dried in a vacuum centrifuge concentrator to remove
the ACN. The dried samples were suspended in 1% TFA, desalted using C-18 NuTips (Glygen,
Columbia, MD), dried again, and finally stored at -20°C until mass spectrometry analysis. The
following steps for mass spectrometric data acquisition and analysis were according to the
descriptions in 2.12.4. All solutions were made with ultrapure water, and all chemicals were
purchased from Sigma unless otherwise noted.
2.13.2 Immunoprecipitation to pull down Mettl21c and Mettl21e binding complex
Vectors containing Mettl21c-FLAG, Mettl21e-FLAG or GFP-FLAG were transduced into
primary myoblasts (70-80% confluent) by adenovirus. Two days post-transduction, cells (from
10 x 100mm plates for each plasmid) were scraped with ice-cold PBS, and then were centrifuged.
The cell pellet was completely resuspended with 1 ml lysis buffer (50mM Tris-HCl, pH 7.5,
150mM NaCl, and 1% NP40 with 1x Protease inhibitor cocktail), on ice, and sonicated with 1
sec pulse and 5 sec interval for 10 times. After 5 min on ice, cell lysate was centrifuged with
14000 rpm at 4°C, and then the supernatant (containing 5 mg proteins determined by the Pierce
bicinchoninic acid assay) was transferred to 50 l pre-cleaned anti-FLAG magnetic beads slurry
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(Sigma, M8823). After incubation on rotator for 3 hours in cold room (4°C), the magnetic beads
were washed three times with lysis buffer. Then, added 500 l ddH2O, up and down several
times to remove salt or solvent remainder (twice). Beads captured proteins were eluted with 100
l of 50 mM triethyl amine (TEA) and 5 mM DTT on thermal shaker (99 °C, 5 min). The protein
elution was centrifuged with CentriVap Concentrator (Labconco) to partially remove TEA, and
then was adjusted to 100 l, pH 8.0 with 1% acetic acid and 15mM Iodoacetamide and placed in
dark for 1 hour. Before desalting the protein elution with StageTips, 1 g trypsin was reacted
with the 100 l adjusted protein elution for 16 hours at 37°C. The following steps for mass
spectrometric data acquisition and analysis were according to the descriptions in 2.12.4.
2.13.3 Mass spectrometry analysis of peptides with methylated lysine
Peptides with methylated lysine were enriched by immunoprecipitation using the PTMScan PanMethyl Lysine Kit (#14809, Cell Signaling) according to the manufacturer’s instructions. In brief,
myoblasts and SOL muscles lysates were prepared using urea lysis buffer (20 mM HEPES pH
8.0, 9 M urea, 2.5 mM sodium pyrophosphate). Protein concentrations were determined and
adjusted to be the same. DTT (4.5 mM) and Iodoacetamide (10 mM) were used to introduce
reduction and alkylation of proteins. The urea was then diluted with 20 mM HEPES pH 8.0 to a
final concentration of approximately 2 M. Before desalting the protein elution with C18 SepPaks, 1 g trypsin was reacted with the 100 l adjusted protein lysates for 16 hours at 37 °C.
Freeze the protein elution (-80 °C freezer) for 2 hr and lyophilize frozen peptide solution for 2
days. Lyophilized peptides were resuspended using the IAP buffer provided in the kit. Then the
IAP-peptides solution was mixed with antibody-bead slurry and incubated on a rotator for 2 hr at
4 °C. The antibody-beads were washed 3 times with IAP buffer and 3 more wash with ddH 2O.
Beads captured peptides were eluted with 100 l of 0.15% trifluoroacetic acid (TFA). Eluted
peptides were purified with StageTips. The following steps for mass spectrometric data
acquisition and analysis were according to the descriptions in 2.12.4.
2.13.4 Mass spectrometry data acquisition and analysis
Dried peptide samples were dissolved in 0.1% formic acid and injected into an Easy nLC 1000
system (Thermo Fisher). The reverse phase chromatography was performed using a C18
capillary column (75 μm i.d., 30 cm length) packed in-house with ProntoPEARL C18 AQ resin
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(2.2 μm bead size, 120Å pore size; Bischoff Chromatography). The electrospray ionization
emitter tip was formed using a laser puller (Model P-2000; Sutter Instrument Co.) before packing
the column. The mobile phase buffer consisted of 0.1% formic acid in ultra-pure water (buffer
A); the elution buffer (buffer B) consisted of buffer A in 80% acetonitrile. The analyses used a
70 minute gradient with a 200 nL/min flow rate as follows: 6% to 30% B over 45 minutes, 30%
to 60% B over 10 minutes, 65% to 95% B over 5 minutes, 95% B for 5 minutes, and then finally
a return to 6% B for 5 minutes. The nanoLC system was coupled online with a high-resolution
hybrid duel-cell linear ion trap orbitrap mass spectrometer (LTQ-Orbitrap Velos; Thermo Fisher).
The mass spectrometer was operated in the data-dependent mode in which a full MS scan from
m∕z 300–1,700 (resolution of 60,000 at m∕z 400) was followed by MS/MS scans of the 15 most
abundant ions after collision induced dissociation (CID). Ions with a charge state of +1 were
excluded, and the mass exclusion time was 90 s. The LTQ-Orbitrap raw files were searched
against the Uniprot Mus musculus database using SEQUEST algorithm built into Proteome
Discoverer (Version 1.4; Thermo Fisher). Peptide precursor mass tolerance was set to 10 ppm,
and MS/MS tolerance was set to 0.8 Da. Searches were performed with full tryptic digestion, and
peptides were allowed a maximum of two missed cleavages; minimum peptide length was set to
5 residues.

2.14 Luciferase assay
Transient transfections were performed with Lipofectamine2000 (Thermo) according to
manufacturer’s instructions. HEK293 cells were grown in Dulbecco’s modified Eagle’s media
(DMEM) supplemented with 10% FBS. Briefly, 100ng of reporter 3xMEF2-luc, 10ng Renilla
and 300 ng of each other plasmids (pCGN-MEF2A, pcDNA3.1-MEF2C-HA, pCGN-MEF2D,
and pcDNA5-Hspa8) was mixed with 2 μl of Lipofectamine2000 and added to 293 cells in 24well plates. After 48 hours, cells were harvested and analyzed with the Dual-Luciferase Reporter
Assay System (Promega). The total amount of DNA added in each transfection was kept
constant by referring to the Renilla signal. The 3xMEF2-luc (Addgene plasmid # 32967), pCGNMEF2A (Addgene plasmid # 32958) and pCGN-MEF2D (Addgene plasmid # 32963) were gifts
from Ron Prywes (Han and Prywes, 1995); the pcDNA3.1-MEF2C-HA was a gift from Andrew
Lassar (Addgene plasmid# 32515) (Kozhemyakina et al., 2009); and the pcDNA5- HSPA8 was a
gift from Harm Kampinga (Addgene plasmid # 19460) (Hageman and Kampinga, 2009).
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2.15 Generation of mutated Hspa8
The pcDNA5-GFP-Hspa8 (K561A) and pcDNA5-GFP-Hspa8 (K561R) were generated using
Q5 Site-Directed Mutagenesis Kit (E0554, NEB) according to the manufacturer’s protocol. In
brief, the pcDNA5-GFP-Hspa8 was amplified by PCR primers (Hspa8-A-f/Hspa8-Mu-r or
Hspa8-R-f/Hspa8-Mu-r). Note the plasmid concentrated should be less than 25 ng. PCR products
were then reacted with KLD enzyme mix (provided in the kit). KLD mix was incubated with
chemically-competent cells. Plasmids were extracted from transfected cells and sequenced to
confirm the correct mutation. To detect the degradation of mutated Hspa8, 293A cells were
transfected with indicated plasmid. Two days after the transfection, 293A cells were treated with
100 µg/ml cycloheximide (Sigma, C7698) for up to 8 hours to block protein translation.

2.16 In vitro methyltransferase reaction
The 293A cells transfected with either pcDNA5-GFP-Hspa8 or pcDNA5-GFP-Hspa8 (K561A),
and pcDNA3.1-Mettl21c plasmids were homogenized in cell extraction buffer (50 mM Tris pH
7.8, 50 mM KCl, 5 mM MgCl2). Protein concentrations were determined using Pierce BCA
Protein Assay Reagent. A portion of cell lysates were used to do western blot to detect the
overexpression of GFP-Hspa8. Methyltransferase reactions were performed in 50 μl volumes for
1 h at 37 °C in methyltransferase reaction buffer [50 mM Tris pH 7.8, 50 mM KCl, 5 mM
MgCl2, 1 mM ATP, 2 μCi [3H]SAM (Perkin-Elmer), 100 ug protein] (Jakobsson et al., 2013).
Then the reaction mixtures were resolved by SDS-PAGE, the gels were dried and subjected to
autoradiography for 2 weeks at -80 °C.

2.17 Lentivirus generation
To deplete endogenous Lamp2a, shRNAs target corresponding to the exon 8 of Lamp2a (5′GACTGCAGTGCAGATGAAG-3′,

5′-CTGCAATCTGATTGATTA-3′,

and

5′-

TAAACACTGCTTGACCACC-3′) were chosen according to the description by Massey et al.
(Massey et al., 2006). The hairpin (sense–loop–antisense) for these sequences was cloned in the
pLKO.1 plasmid. Lentiviral particles containing pLKO.1-Lamp2a-shRNAs or pLKO.1-Scramble
(a gift from David Sabatini, Addgene plasmid # 1864) (Sarbassov et al., 2005) were produced
according to the protocol described by Liu et al. (Liu et al., 2006). Briefly, 293T cells (80%-90%
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confluent) in collagen-coated 10 cm culture dishes were co-transfected with 4 μg of pLKO.1Lamp2a-shRNAs or pLKO.1-Scramble, 4 μg of pHR′-CMV-ΔR8.20vpr, and 2 μg of pHR′CMV-VSV-G using Lipofectamine 2000 (Life Technologies) according to manufacturer’s
protocol. Viruses were harvested 4 times every 12 h from 24 h post-transfection and filtrated
through a 0.45-μm-pore-size filter. Then the viruses were concentrated at 22,000 rpm for 2 h in a
Sorvall T 647.5 rotor. The viral pellets were suspended in 100 μl of TNE buffer (50 mM TrisHCl, pH 7.8, 130 mM NaCl, 1 mM EDTA) and incubated overnight at 4°C. Along with
transduction of Lamp2ashRNAs to myoblast, polybrene (10 μg/ml) and HEPES (10 mM) were
added to increase the transduction efficiency. Puromycin (1 μg/ml) was used to select the
infected myoblasts 2 days post infection.

2.18 Treadmill exhaustion test
I am following our lab protocol to do the treadmill exhaustion test (Castro and Kuang, 2017). In
brief, 2-month-old male mice were trained on the treadmill at 8 m min −1 on a 10% grade for 3
days, 10 min per day. In this test, the speed is initially set at 10 m min−1 for 5 min, 12 m min−1
for 10 min and it is increased 2 m min−1 every 2 min up to a maximum speed of 32 m min−1.

2.19 Sciatic nerve denervation
Mice were anesthetized with ketamine. The hair of the right hind limb was removed with electric
clippers. The skin was aseptically prepared with povidone-iodine solution. Then, make a 1-cm
incision in the skin along with the axis of the femur, and carefully divide the muscle parallel to
and just inferior to the femur. After exposing the sciatic nerve, remove 3-5 mm of the nerve to
prevent healing and regeneration of the nerve. Mice were sacrificed by cervical dislocation 14
days after denervation.

2.20 Proteasome activity assay
TA muscles or differentiated myoblasts were homogenized with 0.5% NP-40. Then the tissue or
cell lysates were centrifuged at 4°C at 13,000 rpm for 10 min. The supernatants were collected
and measured using a Proteasome Activity Assay Kit (ab107921, Abcam) according to the
manufacturer's protocol.
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2.21 Phylogenetic analysis
Phylogenetic analysis was constructed by comparing amino acid sequence of Mettl21e and
Mettl21c with that of other 10 methyltransferases in human MTF16 family using MEGA version
4.0 (Tamura et al., 2007) on the basis of p-distances by the Neighbor-joining method (Saitou and
Nei, 1987). For the construction of the phylogenetic tree, all positions containing gaps and
missing data were eliminated from the multiple alignments. The reliability of the tree obtained
was assessed by bootstrapping using 1000 bootstrap replications (Felsenstein, 1985).

2.22 Data processing and Statistical analysis
Trial experiments or experiments done previously were used to determine sample size with
adequate statistical power. The data are presented with mean and standard deviation (SD) of 5 to
7 biological replicates (the specific number of biological replicates is stated in corresponding
figure legend). Each biological replicate contains certain numbers of technical replicates (e.g.
quantifications of different areas of an immunostaining sample) which were averaged to generate
a data for a biological replicate. In this dissertation, some numbers were presented as relative
value, such as the relative mRNA levels. In this case, the mean value of control or 0-time-point
samples was adjusted as 1, and the values of treatment or the other time-points samples were the
relative fold changes compared to control or 0-time-point samples, respectively. P-values were
calculated using unpaired two-tailed Student’s t-test. P-values <0.05 were considered to be
statistically significant.
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Table 2.1 List of qPCR primers
Gene
qMyh7-f
qMyh7-r
qMyh4-f
qMyh4-r
qMyh2-f
qMyh2-r
qMyh1-f
qMyh1-r
qMEF2A-f
qMEF2A-r
qMEF2C-f
qMEF2C-r
qMEF2D-f
qMEF2D-r
qMettl21c-f
qMettl21c-r
qPGC1α-f
qPGC1α-r
qMettl21e-f
qMettl21e-r
q18s-f
q18s-r
qMyoD-f
qMyoD-r
qMyog-f
qMyog-r
Hspa8-R-f
Hspa8-A-f
Hspa8-Mu-r
Hspa8-f
Hspa8-r
Mettl21c-f
Mettl21c-r
Mettl21cFLAG-r
pLKO.1-f
pLKO.1-r
Mstn-f

Sequence
GCTGGAAGATGAGTGCTCAGAG
TCCAAACCAGCCATCTCCTCTG
GTGATTTCTCCTGTCACCTCTC
GGAGGACCGCAAGAACGTGCTGA
ATGAGCTCCGACGCCGAG
TCTGTTAGCATGAACTGGTAGGCG
TGAAGGGCGGCAAGAAGCAGAT
GCGGAATTTGGCCAGGTTGACA
CAGGTGGTGGCAGTCTTGG
TGCTTATCCTTTGGGCATTCAA
ATCCCGATGCAGACGATTCAG
AACAGCACACAATCTTTGCCT
CGAGATCGCGCTCATCATCTT
AGCCGTTGAAACCCTTCTTCC
AGGAGCTCAAGTCACAGCAACAGA
AGAGGCCAGCACGTAGTCATAACA
TATGGAGTGACATAGAGTGTGCT
CCACTTCAATCCACCCAGAAAG
GGAAGGCTTTCACTTTGCTG
TCCCAGCTCCAATTTCAATC
AACGGTCTAGACAACAAGCTG
AGTGGTCTTGGTGTGCTGAC
GGCTACGACACCGCCTACTA
CGACTCTGGTGGTGCATCTG
TGCCCAGTGAATGCAACTCC
TTGGGCATGGTTTCGTCTGG
AGGATTAACGATGAGGACAAAC
GCGATTAACGATGAGGACAAAC
GCCTTGAAGTTTCTCATCTTC
AAGCGGCCGCATGTCTAAGGGACCTGCAGTTGG
CGTCTAGATTAATCCACCTCTTCAATGG
AAGCGGCCGCATGGATCAGCATCTCCACATAG
CGTCTAGATCACTCCCACTTTAATATCCC
CGTCTAGATCACTTGTCGTCATCGTCTTTGTAGTCCTCCCACTTTAA
TATCCC
AAGCGGCCGCTTTCCCATGATTCCTTCAT
ACTCTAGAACTGCCATTTGTCTCGAGG
AAGCGGCCGCTTTTAAAATGATGCAAAAACTGC
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Table 2.1 continued
Mstn-r
Mettl21e
promoter-f
Mettl21e
promoter-r
Mettl21e-f
Mettl21e-r
Mettl21e-FLAGr

CGTCTAGATCATGAGCACCCACAGCGG
TTCTTCAATCTTTGCTTCAGG
TGAGCTTGTAGTTCTCTAC
AAGCGGCCGCATGGACCTCACAGTAACTCAC
CGTCTAGACTAGGCACTCCTCCGATTTTTC
CGTCTAGACTACTTGTCGTCATCGTCTTTGTAGTCGGCACTCCTCC
GATTTTTC
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METHYLTRANSFERASE LIKE 21E INHIBITS 26S
CHAPTER 3.
PROTEASOME ACTIVITY TO MAINTAIN TYPE IIB MYOFIBER
SIZE

3.1

Abstract

Skeletal muscles are composed of four types of myofibers (I, IIa, IIx/d, and IIb) that are
sequentially larger in size and faster in contraction speed. What regulates the relative size of
these myofibers is unclear. Here I identify methyltransferase like 21e (Mettl21e) as a type IIbmyofiber-enriched protein functioning to maintain myofiber size. Mettl21e expression is upregulated in hypertrophic myostatin null muscles, as a consequence of increased number of IIbmyofibers. Overexpression of Mettl21e in cultured myoblasts promotes myotube hypertrophy,
and Mettl21e knockdown conversely decreases the size of myotubes. Transgenic overexpression
of Mettl21e in the skeletal muscles of mice not only increases myofiber size of normally
innervated muscles, but also ameliorates wasting of denervated muscles. By contrast, knockout
of Mettl21e reduces the size of IIb myofibers without affecting fiber composition. Mass
spectrometry reveals that Mettl21e is associated with subunits of 26S proteasome protein
degradation system. Overexpression and knockout of Mettl21e suppresses and increases the
activity of 26S proteasome, respectively. Notably, proteasome inhibitor rescues the size of
Mettl21e knockdown myotubes. These results demonstrate that Mettl21e functions to maintain
IIb myofiber size through inhibiting protein degradation.

3.2

Introduction

Skeletal muscles are composed of muscle cells or myofibers. Rodent myofibers are
heterogeneous, containing 4 types (I, IIa, IIx, and IIb) classified according to the different
expressions of myosin heavy chain isoforms (Myh7, Myh2, Myh1 and Myh4). Besides the
different physiological and metabolic traits, type IIb myofibers also have the largest size
compared to the other types of myofibers. However, it is unclear what specifically regulate the
type IIb myofiber size.
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The identity of a myofiber is controlled by several of factors, including motor neuron innervation,
hormonal regulation, progenitor cell origin and myofiber type-specific gene expression
(Schiaffino & Reggiani, 2011). Each mature myofiber is monoinnervated by a single motor
neuron, which transmits electrical impulses to a subset of myofibers (Sanes & Lichtman, 1999).
Firing of low motor neurons (motor neurons innervating slow myofibers) generates sustained and
low amplitude elevations in intracellular calcium concentrations, leading to the activation of
calcineurin (Dolmetsch, Lewis, Goodnow, & Healy, 1997). In contrast, fast motor neuron firing
leads to brief calcium transients of high amplitude, which is insufficient to activate calcineurin
(Dolmetsch et al., 1997). Activated calcineurin activates nuclear factor of activated T-cells
(NFAT) and myocyte enhancer factor-2 (MEF2) transcription factors to promote slow myofiberrelated genes transcription (Hogan, Chen, Nardone, & Rao, 2003; Naya et al., 2000; Potthoff,
Wu, et al., 2007; Wu et al., 2001). Besides motor neuron, Twist2-dependent progenitor cells are
recently shown to maintain IIb myofibers (N. Liu et al., 2017). In addition, myofiber-type
specific genes or microRNAs are shown to contribute to myofiber specifications, such as type Ispecific ephrin-A3 and miR-208b (Stark et al., 2015; van Rooij et al., 2009), oxidative myofiberenriched PGC1α (Lin et al., 2002), glycolytic myofiber-specific Tbx15 (K. Y. Lee et al., 2015),
and fast myofiber-enriched Sox6 (Quiat et al., 2011). However, gene programs that regulate
subtypes of fast myofibers are poorly understood.
The upregulated expression of Mettl21e in Mstn knockout (KO) mice and Callipyge sheep which
exhibit robust myofiber hypertrophy and increased abundance of IIb myofibers suggests a
potential link between Mettl21e and type IIb myofibers. In this study, I first performed
expression analysis to pinpoint Mettl21e as a type IIb myofiber enriched protein. I then used
gain-of-function and loss-of-function assays in cell culture and in transgenic mice models to
investigate the in vivo function of Mettl21e in regulating myofiber size. Finally I used mass
spectrometry to identify potential substrate of Mettl21e, and demonstrate that Mettl21e maintains
myofiber size through inhibiting 26S proteasome activity.
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3.3
3.3.1

Results

Mettl21e is upregulated in hypertrophic Mstn KO muscles

I analyzed microarray data comparing gene expression of gastrocnemius (GA) muscles from
wildtype (WT) and Mstn conditional KO mice (Welle et al., 2009b). Three months after Cremediated deletion of Mstn in adult mice, the expression of Mettl21e was 12-fold higher in Mstn
KO mice than in WT mice (Figure 3.1A). Consistently, loss of Mstn increased the expression of
Mettl21e by 8-fold in tibialis anterior (TA) muscles of constitutive Mstn KO mice (Figure 3.1B).
These results suggest that the expression of Mettl21e is negatively correlated with Mstn but
positively associated with muscle hypertrophy.
To determine whether Mettl21e expression is directly regulated by Mstn, I treated primary
myoblasts with an Mstn neutralizing antibody or an Mstn inhibitor (follistatin) in differentiation
media for 5 days. None of the treatments altered the expression of Mettl21e (Figure 3.1C-D). I
also used adenoviral vectors to overexpress Mstn-GFP (MstnOE) or GFP only (control) in
primary myoblasts cultured in growth media. Overexpression (OE) of Mstn did not affect the
expression of Mettl21e (Figure 3.1E). Consistently, I found that the expression level of Mettl21e
was comparable in GA muscles of mice injected with PBS or an Mstn antibody (JA16) for 5
days (Figure 3.1F), prior to the occurrence of Mstn inhibition-induced muscle hypertrophy
(Welle et al., 2009a). These results suggest that Mettl21e expression is associated with muscle
hypertrophy rather than directly regulated by Mstn.
3.3.2

Mettl21e expression is enriched in type IIb myofibers

I next used quantitative PCR (qPCR) to quantify the relative mRNA levels of Mettl21e in various
tissues, and found that Mettl21e was exclusively expressed in the skeletal muscle (Figure 3.2A).
Within the various muscle groups, the expression of Mettl21e was much higher in fast muscles
(TA, EDL and GA) than in slow (SOL) muscles (Figure 3.2B). To directly examine the relative
expression of Mettl21e in various types of myofibers, I isolated individual myofibers from SOL
and EDL muscles and performed qPCR analysis on single myofibers. All individual myofibers
predominantly express one type of Myh isoform, and based on the relative levels of Myh7, Myh2,
Myh1 and Myh4, individual myofibers can be readily grouped into type I (blue column), IIa (red
column), IIx (green column) or IIb (grey column) myofibers (Figure 3.3). Interestingly, all IIb
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myofiber also expressed a medium level of Myh1 (Figure 3.3). Strikingly, Mettl21e expression
was mainly restricted to IIb myofibers, with low levels of expression in type I, IIa and IIx
myofibers (Figure 3.4). On average, the mRNA level of Mettl21e was about 7-fold in IIb
myofibers as in other types of myofibers (Figure 3.4, inset). The single cell analysis results
demonstrate that Mettl21e is a type IIb-enriched gene.
Consistent with the single cell analysis results, the relative mRNA levels of Mettl21e in SOL
muscles of Mstn KO mice were similar to those of WT mice (Figure 3.5A), due to the lack of
IIb myofibers in this muscle despite an apparent myofiber type switching towards IIx myofibers
induced by Mstn KO (Figure 3.5B-C) (Wang et al., 2012). In contrast, the mRNA levels of
Mettl21e in the EDL muscles of Mstn KO mice were 8-fold as high as those in WT mice (Figure
3.6A), corresponding to an apparent increase in the abundance of IIb myofibers and upregulation
of Myh4 gene expression in the Mstn KO EDL muscles (Figure 3.6B-C) (Wang et al., 2012).
These results further confirm that upregulation of Mettl21e expression in the Mstn KO muscles is
due to increases in the number of type IIb myofibers.
3.3.3

Mettl21e is regulated by MyoD

I next investigated the transcriptional factor regulating Mettl21e. During myoblasts
differentiation, the expression of Mettl21e was slightly increased at day 1 post-differentiation
and strikingly up-regulated at day 3 post-differentiation (Figure 3.7A). MyoD is a transcription
factor mediating myoblast differentiation through binding to E-box motifs (Hughes et al., 1993;
Mozdziak et al., 1999; Rudnicki et al., 1993). In parallel with the distribution of Mettl21e in
myofibers, MyoD also has the highest expression level in IIb myofibers (Figure 3.7B).
Intriguingly, there are two E-box motifs located in the proximal promoter of Mettl21e (Figure
3.7C). Therefore, I used chromatin immunoprecipitation (ChIP) to determine if MyoD directly
binds to Mettl21e promoter. ChIP assay using the MyoD antibody detected a 3-fold enrichment
of the DNA sequences containing the E-boxes in Mettl21e promoter, compared with the control
group using an IgG antibody (Figure 3.7C). To verify MyoD regulates the expression of
Mettl21e, I overexpressed MyoD with an adenoviral vector in primary myoblasts. The
overexpression of MyoD resulted in a 2.4-fold upregulation of Myog, an established target of
MyoD, and a 3-fold upregulation of Mettl21e (Figure 3.8A). In addition, I further investigated
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the expression of Mettl21e in MyoD KO C2C12 cell lines, which were generated by the
CRISPR/Cas9 technique (Wang et al., 2017a). Loss of MyoD decreased the expression of
Mettl21e by over 3-fold (Figure 3.8B). Taken together, I conclude that MyoD regulates the
expression of Mettl21e.
3.3.4

Mettl21e controls myotube size in cultured myoblast

The coding sequence for the Mettl21e was cloned from myoblasts and ligated to the PacI site of
To explore the function of Mettl21e, I first used adenovirus to overexpress Mettl21e-GFP
(Mettl21eOE) or GFP only (as control) in primary myoblasts. Mettl21eOE led to 200-fold increase
in the mRNA level of Mettl21e (Figure 3.9A). As Mettl21e is mainly expressed after induction
of myoblast differentiation in WT myoblasts, I mainly focused on post-differentiation myotubes.
After differentiation for 3 days, Mettl21eOE myoblasts formed shorter and wider myotubes than
did the control myoblasts (Figure 3.9B). Quantitative analysis indicated that Mettl21eOE
significantly increased the diameter of myotubes without changing fusion index (Figure 3.10AB). Mettl21eOE did not change the protein levels of myogenic differentiation related MyoD and
Myog (Figure 3.10C), indicating that Mettl21e regulates myotubes size without affecting
differentiation. Consistent with the larger myotube size, Mettl21eOE myotubes expressed higher
levels of Myh (blotted with the MF20 antibody) than did the control myotubes (Figure 3.10C).
I also established C2C12 myoblast cell lines that stably overexpress Mettl21e (Figure 3.11A).
Proliferation of myoblasts was examined using a proliferation marker, Ki67. Whereas 77% of
control myoblasts were Ki67+, only 31-46% of Mettl21eOE myoblasts were Ki67+, suggesting
that Mettl21eOE inhibited myoblast proliferation (Figure 3.11B-C). After differentiation for 3
days, Mettl21eOE myoblasts formed larger myotubes than did the control myoblasts, with 1.9 to
3.2-fold increase in diameter (Figure 3.11D-E). These in vitro results consistently support a role
of Mettl21e in myotube size regulation.
In addition to the gain-of-function study, I performed short hairpin RNA (shRNA) to knock
down Mettl21e in myotubes. Four adenoviral shRNA-GFP vectors (Sh1-Sh4) were constructed;
three of them target coding DNA sequence (CDS), and one targets three prime untranslated
region (3’UTR) (Figure 3.12). Sh1-Sh4 reduced the expression of Mettl21e by 99%, 0%, 52%
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and 92%, respectively (Figure 3.12). Sh1 and Sh4 were thus chosen to knockdown (KD)
Mettl21e, and Sh2 was used as a negative control. Myoblasts were transduced with the Sh1, Sh2,
Sh4 or control (adenoviral-GFP vector) vectors for two days, and then were induced to
differentiate for 3 days. As expected, myotubes treated with Sh2 had a similar morphology to
control myotubes (Figure 3.13A). In contrast, myotubes treated with Sh1 or Sh4 were thinner
than control myotubes (Figure 3.13A). Quantitative analysis showed that Mettl21eKD decreased
the fusion index and the diameter of myotubes (Figure 3.13B-C). Consistent with the smaller
myotube size, Mettl21eKD myotubes expressed lower levels of Myh than did the control
myotubes (Figure 3.13D). Collectively, our cell culture data demonstrate a positive role of
Mettl21e in myofiber size regulation.
3.3.5

Transgenic overexpression of Mettl21e in muscle increases myofiber size

To further study the function of Mettl21e in vivo, we generated transgenic mice that expressed
Mettl21e (Mettl21eOE) under control of regulatory elements of muscle creatine kinase (MCK)
gene which is specifically expressed in skeletal and cardiac muscles (Johnson et al., 1989). Realtime qPCR analysis verified that Mettl21e was exclusively overexpressed in skeletal muscles and
heart of Mettl21eOE mice (Figure 3.14A). Due to the lack of Mettl21e antibody, I used mass
spectrometry to detect the Mettl21e protein in TA muscles of WT and Mettl21e OE mice. I
separated proteins with SDS-PAGE and identified proteins within 25kDa-35kDa range
(containing Mettl21e ~28kDa). A total of 366 proteins were characterized and quantified with
label free quantification (LFQ) intensity. There were 32 proteins that had increased (>2-fold)
LFQ intensity in Mettl21eOE samples. Mettl21e was the top increased (11.9-fold) protein (Figure
3.14B). It is worth to mention that two other methyltransferases, Mettl21c and Mettl10 were not
altered in Mettl21eOE samples, suggesting a successful and specific overexpression of Mettl21e
in Mettl21eOE muscles (Figure 3.14B).
Mettl21eOE mice were indistinguishable from WT mice in terms of gross morphology, body
weight and (TA, EDL, and SOL) muscle weight (Figure 3.15A-B). Total numbers of myofibers
in individual muscles of Mettl21eOE mice were also not affected, but with a trend to decrease in
the OE muscles (Figure 3.15C). Staining for Myh in EDL showed no significant alterations of
myofiber types as well (Figure 3.15D). However, the analysis of minimum ferret diameters of
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myofibers showed that Mettl21eOE mice had less myofibers ranging from 15-25 µm, but more
myofibers ranging from 30-35 µm than did WT mice (Figure 3.16A), suggesting a shift to the
larger size distribution. Consistently, protein levels of Myh were increased by 2-fold in
Mettl21eOE mice compared with that in WT mice (Figure 3.16B).
I further investigated if Mettl21eOE was able to ameliorate denervation-induced muscle wasting.
At Day14 after denervation, the expression levels of Mettl21e were decreased by around 8-fold
in both WT and Mettl21eOE mice (Figure 3.16C). This is accompanied by ~52% drop in the
weight of TA muscles in WT mice, but only ~38% weight drop in Mettl21e OE mice (Figure
3.17A). In agreement with less muscle loss, denervated Mettl21e OE mice had larger myofiber
sizes than denervated WT mice (Figure 3.17B). Sizes of denervated Mettl21eOE myofibers
mainly ranged from 20-40 µm with a peak within 25-30 µm, whereas sizes of denervated WT
myofibers mainly ranged from 15-35 µm with a peak within 20-25 µm (Figure 3.17C). These
results further indicate an essential role of Mettl21e in myofiber size maintenance in the absence
of innervation.
3.3.6

Knockout of Mettl21e decreases the size of type IIb myofibers in mice

We also generated Mettl21e knockout (Mettl21eKO) mice using TALEN technique, creating a
single nucleotide deletion in the 5’ region of the Mettl21e gene (Figure 3.18A). This frameshift
mutation generated 4 mutated amino acids (35FIPT38 to
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LSQL38) and a stop condo (TGA),

leading to a truncated Mettl21e protein with only 38 amino acids (Figure 3.18B). The truncated
Mettl21e protein does not contain the functional domain of Mettl21e, indicative of a loss-offunction mutation (Figure 3.18B). There was no distinguishable difference in the overall body
weight (Figure 3.19A). The weights of two representative fast muscles (TA and EDL) were
decreased in the Mettl21eKO mice compared to WT littermates (Figure 3.19B). Interestingly, the
decreases in muscle weight is accompanied by compensatory increase in the weights of
subcutaneous and epididymal white adipose tissues (sWAT and eWAT) (Figure 3.19B). The
weights of other tissues were comparable between WT and Mettl21e KO mice (Figure 3.19C).
I further investigated the histology of fast-twitch muscles. Staining for Myh isoforms in EDL
muscles showed that Mettl21eKO did not change myofiber type composition or myofiber number
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(Figure 3.20A-B). However, type IIb myofibers had smaller size in Mettl21e KO mice than in WT
mice (Figure 3.21A). The analysis of type IIb myofibers diameter showed that Mettl21e KO mice
had less myofibers ranging from 45-50 µm, with a peak shift from 45-50 µm to 40-45 µm
(Figure 3.21B). In contrast, diameters of the other myofiber types (type I+IIa+IIx) were
comparable between WT and Mettl21eKO mice (Figure 3.21C). These results indicate that
Mettl21e specifically regulates the size of type IIb myofibers. After 14 days of denervation, WT
mice lost 51%, whereas Mettl21eKO mice lost 58% of their TA muscle weights (Figure 3.22A).
In agreement with more pronounced muscle loss, type IIb myofibers had smaller size in
Mettl21eKO mice compared to WT mice (Figure 3.22B). Diameter analysis showed that
Mettl21eKO mice had less IIb myofibers ranging from 35-40 µm, and more myofibers ranging
from 20-30 µm, with a peak shift from 30-35 µm to 25-30 µm (Figure 3.22C). These loss-offunction studies provide compelling evidence that Mettl21e is essential for maintaining type IIb
myofiber size.
3.3.7

Mettl21e regulates the activity of 26S proteasome

I next sought to investigate how Mettl21e regulates myofiber size. The cellular localization of
Mettl21e was determined in C2C12 myoblasts transfected with a pcDNA3.1-Mettl21e-FLAG
plasmid. Immunofluorescence with a FLAG antibody showed Mettl21e was localized
exclusively in cytoplasm (Figure 3.23A). The cytoplasm distribution triggered us to identify
Mettl21e associated proteins that might be responsible for the regulation of myofiber size. I used
FLAG antibody to immunoprecipitate (IP) protein complexes from primary myoblasts
transduced with Mettl21e-FLAG or GFP-FLAG adenoviral vectors. Using mass spectrometry, I
identified 2 chaperone proteins (Vcp and Hsp90ab1) and 6 subunits of 26S proteasome (Psmd2,
Psmd7, Psmc3, Psmc4, Psmc5 and Psmc6) specifically in Mettl21e–associated complexes, but
not in GFP–associated complexes (Figure 3.23B). Notably, Vcp and Hsp90 are involved in the
maintenance of 26S proteasome (Dai and Li, 2001; Imai et al., 2003). These results suggest that
Mettl21e interacts with 26S proteasome.
To determine if Mettl21e modulates the function of 26S proteasome, I performed 26S
proteasome activity assay. The 26S proteasome was moderately inhibited (13%) in Mettl21e OE
muscles under normal conditions, and the inhibitory effect was elevated to 30% under
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denervation conditions (Figure 3.23C). In contrast, knockout of Mettl21e increased the activity
of 26S proteasome by 36% under normal conditions and by 30% under denervation conditions in
TA muscles (Figure 3.23D). In addition, Mettl21eKD myotubes had about 50% higher
proteasome activities than had control myotubes (Figure 3.23E). These results indicate that
Mettl21e decreases the activity of 26S proteasome.
To verify that Mettl21e regulates myotube size through proteasome, I inhibited proteasome
activity in control and Mettl21eKD myotubes using bortezomib, an FDA-approved 26S
proteasome inhibitor. To this end, myoblasts were transduced with the adenoviral-GFP vector
(control) and Sh1 (Mettl21eKD) at Day 1 after serum withdrawal. After differentiation for 2 extra
days, myotubes were treated with DMSO or 25nM bortezomib for 2 days. In the absence of
inhibitor, Mettl21eKD myotubes consistently exhibited thinner morphology than did the control
knockdown myotubes (Figure 3.24A). In contrast, there was no distinguishable difference
between control and Mettl21eKD myotubes in the presence of bortezomib (Figure 3.24A).
Quantifications of fusion index and relative myotube diameter showed that bortezomib treatment
blunted the differences between control and Mettl21e KD myotubes (Figure 3.24B). Notably,
bortezomib treatment increased myotube size and fusion index in control myoblasts (Figure
3.24A-B), indicating that fusion of myocytes is proteasome dependent. Consistently, bortezomib
treatment increased the protein levels of Myh in control myotubes and rescued the decreased
expression of Myh in Mettl21eKD myotubes (Figure 3.24C). Together, I conclude that Mettl21e
controls myofiber size through proteasome dependent regulation of protein abundance.
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Figure 3.1 The expression of Mettl21e in tissues and myoblasts
(A) Mettl21e expression in GA muscles from WT and postdevelopmental Mstn KO mice. (B)
Mettl21e expression in TA muscles from WT and constitutive Mstn KO mice. (C, D) Mettl21e
expression in differentiated myoblasts treated with Mstn antibody (C) or Follistatin (D). (E)
Mettl21e expression in myoblasts with Mstn overexpression. (F) Mettl21e expression in GA
muscles with an anti-Mstn antibody (JA16) or PBS. The values (in A and F) were originated
from the published microarray data. Error bars represent mean+s.d. of 6 mice (B) or 5
independent biological experiments (C, D and E). * indicates p < 0.05 (Student’s t-test).
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Figure 3.2 The expression of Mettl21e in skeletal muscles
(A, B) Quantitative PCR (qPCR) showing relative mRNA levels of Mettl21e in different tissues
(A) and in fast-twitch (TA, EDL and GA) and slow-twitch (SOL) muscles (B). N = 6 mice. Error
bars represent mean+s.d. * indicates p < 0.05 (Student’s t-test).
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Figure 3.3 Realtime qPCR analyses of myosin heavy chain genes in isolated myofibers
Myofibers are isolated from SOL and EDL muscles of 4 mice. According to the relative
expressions of myosin heavy chain genes, myofibers were grouped. Blue, red, green and grey
columns represent I, IIa, IIx and IIb myofibers, respectively.
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Figure 3.4 Realtime qPCR analysis of Mettl21e in different types of myofibers
Inset: the average expression of Mettl21e in different types of myofibers. Error bars represent
mean+s.d. * indicates p < 0.05 (Student’s t-test).

Relative mRNA levels

Relative mRNA levels
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Figure 3.5 The expression of Mettl21e in slow twitch muscles of Mstn KO mice
(A, B) Realtime qPCR analysis of Mettl21e (A) and myosin heavy chain genes (B) and in SOL
muscles of WT and Mstn KO mice. (C) Immunostaining of type I (Myh7, Red) and type IIa
(Myh2, Green) myofibers in SOL muscles of WT and Mstn KO mice. Error bars represent
mean+s.d. of 6 mice. * indicates p < 0.05 (Student’s t-test).

Relative mRNA levels

Relative mRNA levels
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Figure 3.6 The expression of Mettl21e in fast twitch muscles of Mstn KO mice
(A) Immunostaining of type IIb (Myh4, Red) and type IIa (Myh2, Green) myofibers in EDL
muscles of WT and Mstn KO mice. (B, C) Realtime qPCR analysis of myosin heavy chain genes
(B) and Mettl21e (C) in EDL muscles of WT and Mstn KO mice. Error bars represent mean+s.d.
of 6 mice. * indicates p < 0.05 (Student’s t-test).

Relative mRNA levels

Relative mRNA levels
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Figure 3.7 MyoD binds with the promoter of Mettl21e
(A) Realtime qPCR analysis of Mettl21e in differentiated myoblasts. N = 6 different batches of
primary myoblasts. (B) The expression of MyoD in different types of myofibers. (C) Fold
enrichments of the E-box region of Mettl21e promoter by MyoD, determined by chromatin
immunoprecipitation. N = 4 independent biological experiments. Error bars represent mean+s.d.
* and different letters indicate p < 0.05 (Student’s t-test).
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Figure 3.8 MyoD regulates the expression of Mettl21e
(A) The expression of Mettl21e in myoblasts with the overexpression of MyoD. N = 6 different
batches of primary myoblasts. (B) The expression of Mettl21e in MyoD knockout myoblasts.
Error bars represent mean+s.d. * and different letters indicate p < 0.05 (Student’s t-test).

Relative mRNA levels
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Figure 3.9 Overexpression of Mettl21e increases myotube size
(A) The expression of Mettl21e in myoblasts transduced with Mettl21e-GFP (Mettl21eOE) or
GFP only (as control) adenoviral vectors. N = 5 independent biological experiments. Error bars
represent mean+s.d. * indicates p < 0.05 (Student’s t-test). (B) Myotubes with adenoviral vectors
were stained by MF20 (Red) and nuclei were counterstained by DAPI (Blue). Scale bar: 100 µm.
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Figure 3.10 The effect of Mettl21e on myotubes
(A, B) Fusion index (A) and relative diameter (B) counted according to the staining in Figure 3.9.
Only GFP+ cells were used for quantification. N = 5 independent biological experiments, with
five different areas analyzed in each experiment. (C) Western blots analysis showing the effect
of Mettl21e overexpression on Myh (MF20), MyoD and Myog. Error bars represent mean+s.d. *
indicates p < 0.05 (Student’s t-test).

Relative mRNA levels
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Figure 3.11 Identification of cell clones with Mettl21e overexpression
(A) The expression of Mettl21e in selected cell clones. (B) Immunostaining of Ki67 (Red) in
Mettl21eOE cell clones. (C) Quantification of Ki67 positive cells. (D) Immunostaining of MF20
(Red) in differentiated Mettl21eOE cells. (E) Fusion index. Scale bar: 100 µm. Error bars
represent mean+s.d. of 5 independent experiments. * indicates p < 0.05 (Student’s t-test).
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Figure 3.12 The targets of Mettl21e shRNAs and the expression of Mettl21e in myotubes
treated with shRNAs
Error bars represent mean+s.d. of 5 independent experiments. * indicates p < 0.05 (Student’s ttest).
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Figure 3.13 Knockdown of Mettl21e decreases myotube size
(A) Myotubes treated with shRNAs were stained by MF20 (Red) and nuclei were counterstained
by DAPI (Blue). Scale bar: 100 µm. (B, C) Fusion index (B) and relative diameter (C) counted
according to the staining in (A). Only GFP+ cells were used for quantification. N = 5 independent
biological experiments, with five different areas analyzed in each experiment. (D) Western blot
analysis showing the effect of Mettl21e knockdown on Myh. Error bars represent mean+s.d. *
indicates p < 0.05 (Student’s t-test).
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Figure 3.14 The expression of Mettl21e in Mettl21eOE mice
(A) Mettl21e expression in different tissues of WT and Mettl21eOE mice. (B) Mass spectrometry
analysis of TA muscles of WT and Mettl21eOE mice. Error bars represent mean+s.d. of 7 mice. *
indicates p < 0.05 (Student’s t-test).
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Figure 3.15 Analysis of WT and Mettl21eOE mice
(A) Relative body weight and (B) muscle tissues weight of WT and Mettl21e OE mice. (C)
Myofiber numbers in skeletal muscles of WT and Mettl21e OE mice. (D) Immunostaining and
quantification of type IIb (Green) and type IIa (Red) myofibers in EDL muscles of WT and
Mettl21eOE mice. Scale bar: 100 µm. Error bars represent mean+s.d. of 7 mice. * indicates p <
0.05 (Student’s t-test).
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Figure 3.16 Transgenic overexpression of Mettl21e increases myofiber size in mice
(A) Size distribution of myofibers in TA muscles of WT and Mettl21e OE mice. (B) Western blots
analysis of Myh in WT and Mettl21eOE mice. (C) Realtime qPCR analysis of Mettl21e in
innervated or denervated EDL muscles. N = 5 pairs of mice. Error bars represent mean+s.d. *
and different letters indicate p < 0.05 (Student’s t-test).
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Figure 3.17 Mettl21eOE alleviates muscle atrophy induced by denervation
(A) Relative weights of denervated muscles, represented as the percentage of contralateral
innervated muscle. (B) Immunostaining of dystrophin (Green) in innervated and denervated TA
muscle sections. Scale bar: 100 µm. (C) Size distribution of myofibers in denervated TA
muscles. N = 5 pairs of mice. Error bars represent mean+s.d. * indicates p < 0.05 (Student’s ttest).
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Figure 3.18 Genomic sequence of mutated Mettl21e gene
(A) Sequencing chromatograms of targeted region of Mettl21e gene. Reading frame is
underlined. The stop codon is highlighted by line and dot in mutated Mettl21e gene. (B)
Annotated Mettl21e protein in WT and Mettl21eKO mice. Numbers indicate the sites of amino
acids in annotated protein. Conserved functional domain of Mettl21e is in grey box.
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Figure 3.19 Weights of WT and Mettl21eKO mice
(A) Relative body weight, (B) muscle and adipose tissues weight and (C) the other tissues weight
of WT and Mettl21eKO mice. Error bars represent mean+s.d. of 7 mice. * indicates p < 0.05
(Student’s t-test).

62

Figure 3.20 Myofiber type and myofiber number of WT and Mettl21e KO mice
(A) Immunostaining and quantification of type IIb (Green) and type IIa (Red) myofibers in EDL
muscles of WT and Mettl21eKO mice. Scale bar: 100 µm. (B) Myofiber numbers in skeletal
muscles of WT and Mettl21eKO mice. Error bars represent mean+s.d. of 7 mice. * indicates p <
0.05 (Student’s t-test).
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Figure 3.21 Mettl21eKO decreases type IIb myofiber size
(A) Immunostaining of type IIb (Red) myofibers in WT and Mettl21e KO mice. (B, C) Size
distribution of type IIb myofibers (B) or the other types (IIa+IIx+I) of myofibers (C) in TA
muscles of WT and Mettl21eKO mice. N = 5 pairs of mice. Error bars represent mean+s.d. *
indicates p < 0.05 (Student’s t-test).
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Figure 3.22 Mettl21eKO decreases type IIb myofiber size in denervated condition
(A) Relative weights of denervated muscles, represented as the percentage of contralateral
innervated muscle. (B) Immunostaining of type IIb myofibers (Red) in innervated and
denervated TA muscle sections. (C) Size distribution of type IIb myofibers in denervated TA
muscles. Scale bar: 100 µm. N = 5 pairs of mice. Error bars represent mean+s.d. * indicates p <
0.05 (Student’s t-test).
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Figure 3.23 Mettl21e regulates the activity of 26S proteasomes
(A) Construction of a flagged Mettl21e overexpression plasmid (Mettl21e-FLAG) and its
intracellular localization (Red) after transfected into C2C12 myoblasts. Scale bar: 50 µm. (B)
Mass spectrometry analysis of Mettl21e binding proteins. (C) The activity of 26S proteasome in
innervated and denervated TA muscles of WT and Mettl21eOE mice. (D) The activity of 26S
proteasome in innervated and denervated TA muscles of WT and Mettl21e KO mice. (E) The
activity of 26S proteasome in control and Mettl21eKD myotubes. Error bars represent mean+s.d.
of 5 independent biological experiments. * indicates p < 0.05 (Student’s t-test).
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Figure 3.24 Bortezomib rescues myofiber size reduction induced by Mettl21eKD
(A) Control and Mettl21eKD cell were treated with DMSO or Bortezomib for 2 days. The
differentiated myoblasts were stained by MF20 (Red) and nuclei were counterstained by DAPI
(Blue). Scale bar: 100 µm. (B) Fusion index and relative diameters of myotubes counted
according to the staining in (A). Only GFP+ cells were used for quantification. (C). Western blots
analysis of Myh. Error bars represent mean+s.d. of 5 independent biological experiments. *
indicates p < 0.05 (Student’s t-test).
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3.4

Discussion

In this study, I report the expression and function of a novel methyltransferase gene, Mettl21e.
Mettl21e is one of the top up-regulated genes in Mstn KO fast-twitch muscles (Welle et al.,
2009b), but I show that it is not directly regulated by Mstn. Instead, increased expression of
Mettl21e was due to increases in the abundance of IIb myofibers in Mstn KO fast-twitch muscles
(Amthor et al., 2007). This finding also explains the up-regulation of Mettl21e in hypertrophic
muscles of Callipyge sheep (Fleming-Waddell et al., 2009), in which a substantial increase of
type IIb myofibers in hypertrophic muscles was reported (Bidwell et al., 2014; Carpenter et al.,
1996). Interestingly, the counterpart of Mettl21e in human is denoted as a unitary pseudogene
(Zhang et al., 2010). Human METTL21E was possibly inactivated by a splice-junction mutation
(AG to TA) located at the acceptor-splice site of its second intron. And the splice-junction
mutation is accompanied by the lack of detectable type IIb myofibers in human skeletal muscles
(Smerdu et al., 1994).
Mettl21e is located in the cytoplasm. This cytoplasmic localization indicates that Mettl21e is not
a histone methyltransferase that functions to regulate gene transcription. Our mass spectrometry
data show that Mettl21e binds with subunits of 26S proteasome, a large multi-protein complex
mediating muscle proteins degradation and consequently affecting myofiber size (Bedford et al.,
2010; Bhatnagar et al., 2012; Bonaldo and Sandri, 2013). Mettl21eOE inhibits the proteasome
activity, thereby increasing myofiber size. In contrast, Mettl21eKO or Mettl21eKD increases the
proteasome activity, hence reducing myofiber size. Moreover, inhibition of proteasome activity
rescues Mettl21eKD-induced myofiber size reduction, demonstrating that Mettl21e regulates
myofiber size through proteasome. Motor innervation inhibits proteasome activity to maintain
muscle mass and myofiber size (Tang et al., 2014), which overlaps the function of Mettl21e.
Thus, the inhibitory effect of Mettl21eOE on proteasome activity is less obvious in innervated
muscles than in denervated muscles. Notably, proteasome activity is also required for the
completion of cell cycle (Bassermann et al., 2014). It is therefore plausible to speculate that
Mettl21eOE inhibits myoblast proliferation also through the inhibition of proteasome activity.
It remains to be determined in future studies how Mettl21e regulates 26S proteasome activity.
Current knowledge indicates that non-histone methylation regulate protein functions through the
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crosstalk with other posttranslational modification or through changing protein-protein
interactions (Biggar and Li, 2015; Zhang et al., 2012). Phosphorylation of Rpt3 or Rpt6 has been
shown to enhance proteasome activity (Guo et al., 2016; Ranek et al., 2013). It is possible that
Mettl21e methylates the subunits of proteasome to affect their phosphorylation, or to directly
modulate their activities. Aside from the direct regulation, Mettl21e might methylate
proteasome-binding molecular chaperones, Vcp and Hsp90, to indirectly modify proteasome
activity (Besche et al., 2009; Imai et al., 2003). Vcp maintains the activity of 26S proteasome
through binding and antagonizing the inhibitory function of the proteasome inhibitor PI31
(Clemen et al., 2015). METTL21D has been shown to methylate human VCP at lysine residue
K315 (Cloutier et al., 2013; Kernstock et al., 2012). However, the effect of methylation on VCP
is undetermined (Kernstock et al., 2012). Hsp90 physically binds with 26S proteasome to
mediate its assembly (Imai et al., 2003). A lysine methyltransferase Smyd2 methylate Hsp90 at
K615 (Donlin et al., 2012). This methylation is required for Hsp90-titin interaction and helps to
maintain titin stability (Donlin et al., 2012). In contrast, the methylation of Hsc70 on lysine
residue K561 perturbs its binding with C terminus of Hsc70-interacting protein (Zhang et al.,
2015). Hence, the effect of methylation on molecular chaperones is highly methylation site
dependent. It is possible that Mettl21e methylates Hsp90 and VCP to interrupt their binding with
proteasome and PI31, respectively, to indirectly regulate the activity of 26S proteasome.
Understanding the detailed mechanisms will extend our knowledge about molecular regulation
of proteasome activity.
Our finding also helps to explain the myofiber-size paradox: where oxidative myofibers are
smaller than glycolytic myofibers despite the higher myonuclei content (per volume) and higher
rates of protein synthesis in the oxidative myofibers (Goldberg, 1967; Tseng et al., 1994; van
Wessel et al., 2010). One explanation for this paradox is due to differential rate of protein
degradation, which is mainly mediated by the ubiquitin-proteasome system. This system includes
two discrete and successive processes: conjugating substrate proteins with multiple ubiquitin
molecules; and the subsequent degradation of the tagged proteins by the 26S proteasome (Lecker
et al., 2006). The conjugation of ubiquitin to lysine residues of substrate proteins requires three
ATP-dependent enzymatic steps (Lecker et al., 2006). E3 is the key enzyme in the conjugation
process. Two muscle-specific E3, muscle atrophy F box (Atrogin-1/MAFbx) and muscle RING

69
finger 1 (MuRF1), are found to have a higher expression in oxidative muscles than in glycolytic
muscles (Bodine et al., 2001; van Wessel et al., 2010). Thus, the higher rates of protein
degradation in the oxidative muscles may have underlined their smaller size. Here, I provide
evidence that type IIb myofibers also employ an active mechanism to maintain their size through
Mettl21e mediated inhibition of 26S proteasome.
Finally, I found that Mettl21eKD decreased myoblasts fusion. However, I do not have direct
evidence to support a role of Mettl21e in myoblast fusion. First, mass spectrometry data fails to
identify any Mettl21e binding proteins that are known to be regulators of myoblasts fusion
(Abmayr and Pavlath, 2012). Second, Mettl21e does not change the expression of MyoD and
Myog, which are transcriptional factors key for myogenic differentiation (Hasty et al., 1993;
Rawls et al., 1998). A potential link between Mettl21e and myoblast fusion is again based on the
observation that the proteasome inhibitor bortezomib promotes myoblast fusion. Thus, lack of
Mettl21e may inhibit myoblast fusion through enhanced 26S proteasome activity which could
degrade proteins controlling myoblast fusion. In summary, our study identifies Mettl21e as a
type IIb myofiber-enriched protein functioning to maintain type IIb myofiber size.
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METHYLTRANSFERASE LIKE 21C MODULATES
CHAPTER 4.
CHAPERONE-MEDIATED AUTOPHAGY TO CONTROL MUSCLE
GENE EXPRESSION IN SLOW MYOFIBERS

4.1

Abstract

Development and maintenance of adult tissues require coordinated changes in gene regulatory
network. Myocyte enhancer factor-2 (MEF2) transcriptional factors are key for myogenic
differentiation, but their levels or activities must be suppressed in post-differentiation skeletal
muscles. Here we describe a molecular mechanism that mediates stage-dependent degradation of
MEF2A and MEF2D in adult muscles. We identify methyltransferase like 21c (Mettl21c) as a
mature slow myofiber-specific protein that tri-methylate heat shock protein 8 (Hspa8) at lysine561 to enhance its stability. Stabilization of Hspa8, a key component of chaperone-mediated
autophagy (CMA), consequently promotes selective degradation of MEF2A and MEF2D.
Overexpression of Hspa8 or Mettl21c similarly reduces MEF2A and MEF2D levels in
myoblasts. Conversely, knockout of Mettl21c in mice reduces the trimethylation of Hspa8 and
increases the levels of MEF2A and MEF2D, leading to upregulation of slow muscle-specific
genes in slow myofibers. These results establish Mettl21c as a novel regulator of the CMA
machinery to suppress developmental factors in mature muscle cells.

4.2

Introduction

The skeletal muscle provides body support, powers body movements, and regulates systemic
energy homeostasis. Mammalian skeletal muscles are heterogeneous, composing two general
types of muscle cells (myofibers): the slow-twitch (type I) and fast-twitch (type II) myofibers
(Schiaffino and Reggiani, 2011). The myocyte enhancer factor-2 (MEF2) transcription factor, a
key regulator of muscle development and regeneration, is required for the establishment of type I
myofibers (Liu et al., 2014; Potthoff et al., 2007a; Potthoff et al., 2007b). Notably, the activity of
MEF2 should be controlled, or aberrantly enhanced MEF2 activity leads to myotonia (Wu and
Olson, 2002). Current understanding about the regulation of MEF2 lies on the transcriptional
activity level. MEF2 is activated by Ca2+/calmodulin kinases (Passier et al., 2000), calciumactivated serine/threonine phosphatase calcineurin (Wu et al., 2001), and mitogen-activated
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protein kinases, such as p38 and ERK5 (Ornatsky et al., 1999; Yang et al., 1998). By contrast,
the activity of MEF2 is repressed by class II histone deacetylases (HDACs) (Chang et al., 2004;
McKinsey et al., 2000). It is unclear whether the protein level of MEF2 is controlled in skeletal
muscles.
The autophagy-lysosome system degrade cytoplasmic organelles and other macromolecules for
recycling in response to nutrient stress (Eskelinen and Saftig, 2009). Three types of autophagy
are classified based on the route of how cytoplasmic materials are delivered to lysosome. In
macroautophagy, cytoplasmic materials are wrapped inside a spherical membrane structure and
then fused with lysosome for degradation. In microautophagy, cytoplasmic materials are trapped
in the lysosome trough membrane invagination. In chaperone-mediated autophagy (CMA),
cytoplasmic proteins with CMA-targeting motif are recognized and delivered by heat shock
protein 8 (Hspa8/Hsc70) to lysosome through the lysosomal receptor lysosomal-associated
membrane protein 2A (Lamp2a) (Eskelinen and Saftig, 2009). Macroautophagy contributes to
muscle mass loss in stressful conditions, such as denervation, fasting or oxidative stress
(Dobrowolny et al., 2008; Furuno et al., 1990; Pietri-Rouxel et al., 2010). Macroautophagy not
only recycles cytoplasmic material to compensate for nutrient deprivation but also selectively
degrade organelles to maintain their number and quality. In this regard, basal macroautophagy is
required for muscle homeostasis. Microautophagy was reported to mediate glycogen uptake into
lysosomes (Raben et al., 2008), CMA to mediate the degradation of two major isoforms of the
MEF2 transcription factor, MEF2A and MEF2D, in neuronal cells (Yang et al., 2009; Zhang et
al., 2014). However, the roles of microautophagy and CMA in skeletal muscles are largely
unknown.
In this study, I used the Mettl21cLacZ knockin/knockout mouse model to investigate the
expression and function of Mettl21c in vivo. I found that Mettl21c was selectively expressed in
type I myofibers. Using loss-of-function and gain-of-function approaches, I demonstrate that
Mettl21c methylates and stabilizes Hspa8 to promote CMA-mediated degradation of MEF2A
and MEF2D, and consequently controlling the expression of slow muscle related genes. These
data reveal a novel function of Mettl21c in the skeletal muscle.

72
4.3
4.3.1

Results

Mettl21c is specifically expressed in type I myofibers

As the first step to understand its function, I characterized the expression of Mettl21c in adult
mice. Realtime qPCR analysis showed that Mettl21c was specifically expressed in mouse
skeletal muscle (Figure 4.1A). Within various muscle groups, the highest levels of Mettl21c
were detected in the slow-twitch soleus (SOL) muscle, with intermediate levels detected in the
fast/slow mixture gastrocnemius (GA) muscles, and lowest levels in the fast tibialis anterior (TA)
and extensor digitorum longus (EDL) muscles (Figure 4.1B). This observation prompted us to
further investigate the expression of Mettl21c in individual fast or slow myofibers. Single
myofibers were isolated from SOL and EDL muscles, and Mettl21c together with Myh levels in
individual myofibers were determined using qPCR. I found that the mRNA level of Mettl21c
was 12-fold in type I myofibers as in the other types (IIa, IIx, IIb) of myofibers, which had
similar levels (Figure 4.1C). These results suggest that Mettl21c expression is enriched in type I
myofibers.
I further analyzed the endogenous expression of Mettl21c using Mettl21cLacZ/+ mice, which
contain the β-Gal reporter targeted to exon 2 to 5 of Mettl21c (Figure 4.2A). Whole-mount XGal staining of skeletal muscles showed dark-blue color across the whole SOL muscle, and in
type I myofibers-enriched regions of gastrocnemius (GA) and diaphragm muscles, but no
discernable signals in TA and EDL muscles (Figure 4.2B). To confirm type I myofiber-specific
expression of Mettl2c, I further performed immunofluorescence staining of Myh7 and X-Gal
staining in serial sections of SOL, GA, TA, and EDL muscles. I found that X-Gal staining was
exclusively in Myh7+ (type I) myofibers in every muscle examined (Figure 4.2C and Figure
4.3). Interestingly, type I myofibers had weaker X-Gal signals in fast (EDL and TA) muscles
than in slow (SOL and GA) muscles (Figure 4.2C and Figure 4.3). I conclude that Mettl21c is
specifically expressed in type I myofibers.
4.3.2

Mettl21c is only expressed in mature but not in developing slow myofibers

I utilized Mettl21cLacZ/+ mice to detect spatial-temporal expression of Mettl21c during muscle
development. Whole-mount X-Gal staining showed no discernible positive signals in limb
muscles of E18.5 embryos (Figure 4.4). Additionally, there were no X-Gal signals in SOL
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muscle of postnatal day 3 (P3) mice, though Myh7+ slow myofibers were readily detectable at
the same stage (Figure 4.5A), indicating that the expression of Myh7 precedes that of Mettl21c.
X-Gal signals were first shown in a group of Myh7+ myofibers in SOL muscles of P7 mice
(Figure 4.5B). The X-Gal signals became stronger and nearly all Myh7+ myofibers had positive
X-Gal staining in SOL muscle of P10 mice (Figure 4.5C). In EDL muscle, we did not find XGal signals till P10 when less than half of the Myh7+ myofibers were LacZ+ (Figure 4.6). At P14,
a subset of Myh7+ myofibers was still negative for X-Gal signals, suggesting heterogeneity of
Myh7+ myofibers in EDL muscles (Figure 4.6). Consistent with the X-Gal staining patterns,
mRNA levels of Mettl21c were low from E18.5 to P3, then upregulated at P7, reaching the
highest level at P10 in hindlimb muscles (Figure 4.5D). Hence, the expression of Mettl21c is
associated with the maturity of Myh7+ myofibers.
I also investigated the expression of Mettl21c during SOL muscle regeneration after injuries
induced by cardiotoxin (CTX) injection. Mettl21c mRNA levels was sharply decreased by more
than 90% within 3 days after CTX-induced muscle degeneration, and gradually increased in the
following 2 weeks, reaching the maximal levels at day 14 post CTX-injury (Figure 4.7A). In
parallel, I performed immunofluorescence and X-Gal staining on sections of regenerated SOL
muscles. At day 7 post CTX injection, only a small number of regenerating Myh7 + myofibers
had weak X-Gal signals (Figure 4.7B), indicating that Mettl21c is not expressed in newly
regenerated type I myofibers. At day 14 post CTX injection, a substantial number of regenerated
myofibers expressed Myh7, accompanied by increased levels X-gal signal specifically in Myh7 +
myofibers (Figure 4.7C). These results consistently support the notion that the expression of
Mettl21c is associated with the maturation of type I myofibers.
The absence of Mettl21c during the early stages of muscle development and regeneration led us
to hypothesize that Mettl21c is not expressed in myogenic progenitors (myoblasts). To test this,
primary myoblasts were isolated from Mettl21cLacZ/+ or Mettl21cLacZ/LacZ mice, and induced to
differentiate. As expected, no X-Gal signals were detected in the primary myoblasts, even after
differentiated into myotubes (Figure 4.8A). In addition, the mRNA levels of Mettl21c were
comparable between Mettl21cLacZ/+ (HET) and Mettl21cLacZ/LacZ (KO) myotubes, indicative of the
lack of Mettl21c expression in the Mettl21cLacZ/+ myotubes (Figure 4.8B). These results
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collectively indicate that the expression of Mettl21c is absent during myogenesis and increased
with the maturation of type I myofibers.
4.3.3

Mettl21c is responsible for methylation of Hspa8

I next sought to characterize the function of Mettl21c. To do this I first determined the cellular
localization of Mettl21c after expressing a Flag-tagged Mettl21c protein in C2C12 myoblasts.
Immunostaining with a FLAG antibody showed signals in both cytoplasm and nucleus (Figure
4.9A). To find out the substrate of Mettl21c, I used FLAG antibody to immunoprecipitate (IP)
protein complexes from primary myoblasts transduced with Mettl21c-FLAG or GFP-FLAG
adenoviral vectors (Figure 4.9B). SDS-PAGE analysis of the proteins obtained by IP revealed a
~70 kDa protein co-purified with Mettl21c but not with GFP (Figure 4.9C). Using affinity
purification-mass spectrometry (AP-MS), I identified several chaperone proteins specifically in
Mettl21c–associated complexes, but not in GFP–associated complexes (Figure 4.10A). Among
these chaperone proteins, Hspa5 and Hspa8 have a molecular weight around 70 kDa. IP analysis
confirmed that Mettl21c binds with endogenous Hspa8 but not with Hspa5 in primary myoblasts
(Figure 4.10B). These results demonstrate that Mettl21c physically interacts with Hspa8.
Then I utilized AP-MS to characterize methylated peptides in primary myoblasts transduced with
Mettl21c-GFP (Mettl21cOE) or GFP only (as control) adenoviral vectors. To increase the
detection efficiency, methylated peptides were enriched by IP using a pan-methyl lysine
antibody (Figure 4.11A). Hspa8 was identified to be exclusively trimethylated at lysine (K) 561
in primary myoblasts (Figure 4.11B). Notably, the abundance of the trimethylated Hspa8
peptide was 5-fold higher in Mettl21cOE myoblasts than in control myoblasts, indicating that
Mettl21c was responsible for the trimethylation (Figure 4.11C). To further test whether Hspa8
K561 was subject to Mettl21c-catalyzed methylation, 293A cell lysates containing Mettl21c and
control (K561) or mutated (K561A) GFP-Hspa8 were incubated with [ 3H] SAM, allowing for the
detection of methylated substrates by fluorography of SDS-PAGE separated proteins. I found
that the 3H signal was increased in the band corresponding to Hspa8 and GFP-Hspa8 with the
overexpression of Mettl21c (Figure 4.12). In contrast, there was no 3H signal in mutated GFPHspa8 (Figure 4.12). In addition, the 3H signal in endogenous Hspa8 was competitively
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decreased by the mutated GFP-Hspa8 (Figure 4.12). These results provide compelling evidence
to support that Mettl21c methylates Hspa8 at K561.
Next I investigated methylated peptides in SOL muscles of Mettl21c LacZ/LacZ (KO) mice. To
achieve this, methylated peptides were enriched from SOL muscles of Mettl21c +/+ (WT) or
Mettl21cKO mice (Fig. 3I). AP-MS analysis revealed that Hspa8 was either dimethylated or
trimethylated at K561 (Figure 4.13). Intriguingly, loss of Mettl21c decreased the abundance of
trimethylated Hspa8 peptide by 51%, whereas dimethylated Hspa8 peptide was increased by 11%
(Figure 4.13). These results confirm that muscle endogenous Mettl21c mediate the
trimethylation of Hspa8 at K561 in vivo.
4.3.4

K561 methylation stabilizes Hspa8 and inhibits MEF2A and MEF2D

I next investigated the biological consequences of K561 methylation on Hspa8. It has been
reported that the methylation perturbs interaction between Hspa8 and an E3 ubiquitin ligase Cterminus of Hsp70 Interacting Protein (CHIP), leading to decreased ubiquitination on Hspa8
(Zhang et al., 2015). Thus, I hypothesize that the K561 methylation prevents Hspa8 from
degradation by the ubiquitin-proteasome system. I transfected 293A cells with K561R or K561A
mutant pcDNA5-GFP-Hspa8 plasmids to mimic methylated or unmethylated K561, and treated
the 293A cells with a protein synthesis inhibitor cycloheximide (CHX) to observe the
degradation of the two mutants (Figure 4.14A). Whereas the protein level of K561A mutant was
decreased after CHX treatment, the protein level of K561R mutant was unchanged (Figure
4.14A). The result indicates that K561 methylation increases the stability of Hspa8.
It has been reported that Hspa8 targets MEF2A and MEF2D to lysosome for degradation through
chaperone-mediated autophagy (CMA) in neurons (Yang et al., 2009; Zhang et al., 2014). I
found that Hspa8 selectively inhibited the transcriptional activities of MEF2A and MEF2D
(Figure 4.14B). In addition, differentiated myotubes transduced with Hspa8-GFP (Hspa8OE) had
lower levels of MEF2A and MEF2D than did control myotubes transduced with GFP only
adenoviral vector, without changing the transcription of MEF2A and MEF2D (Figure 4.15A-B),
indicating a conserved function of Hspa8 in mediating the degradation of MEF2A and MEF2D.
The expression of PGC1α and Myh7, target genes of MEF2 (Czubryt et al., 2003; Potthoff et al.,
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2007a; Wu et al., 2000), were consequently decreased in Hspa8 OE myotubes (Figure 4.15B).
Meanwhile, the level of Myh7 and the percentage of Myh7+ myotubes were decreased by
Hspa8OE (Figure 4.16A-B). These results establish a role of the methylation in regulation of slow
muscle related proteins.
4.3.5

Mettl21c overexpression decreases the levels of MEF2A and MEF2D through CMA

To further study the effect of methylation in myotubes, differentiated myoblasts were transduced
with Mettl21c-GFP (Mettl21cOE) or GFP only (as control) adenoviral vectors. The expression of
Mettl21c was over 2000-fold higher in Mettl21cOE myotubes than in control myotubes (Figure
4.17A). The differentiation of Mettl21cOE myoblasts was normal, while the percentage of Myh7+
myotubes and the level of Myh7 were decreased by Mettl21cOE (Figure 4.17B-C). Consistent
with the effect of K561 methylation on the stability of Hspa8, Mettl21c OE increased the level of
Hspa8 (Figure 4.18A). As with Hspa8OE, Mettl21cOE also decreased the levels of MEF2A and
MEF2D, without changing the expressions of MEF2A and MEF2D transcripts (Figure 4.18A-B).
Meanwhile, the expressions of Pgc1α and Myh7 were reduced by Mettl21cOE (Figure 4.18B).
To test whether Hspa8-mediated CMA is involved in the degradation of MEF2A and MEF2D
(Yang et al., 2009; Zhang et al., 2014), I selectively blocked CMA by silencing Lamp2a using
lentiviral shRNA (Massey et al., 2006). Lamp2a shRNA efficiently reduced the expression of
Lamp2a, without changing the level of Hspa8, suggesting that Hspa8 was not degraded through
CMA (Figure 4.19). In contrast, MEF2A and MEF2D accumulated after Lamp2a knockdown
(Figure 4.19), revealing a conserved autophagy pathway in degradation of MEF2A and MEF2D
in both myoblasts and neurons (Yang et al., 2009; Zhang et al., 2014). Importantly, Lamp2a
silencing rescued the decreased level of MEF2A and MEF2D in Mettl21c OE myotubes, despite
the increased level of Hspa8 (Figure 4.19), indicating that the CMA pathway is required for
Mettl21c and Hspa8 to degrade MEF2A and MEF2D. These results reveal that Mettl21c
increases the level of Hspa8 through methylation and consequently promote CMA-mediated
degradation of MEF2A and MEF2D.
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4.3.6

Loss of Mettl21c increases the levels of MEF2A and MEF2D in vivo

We next investigated the function of Mettl21c in vivo using Mettl21cLacZ/LacZ (KO) mice. To
exclude the influence of β-Gal, we compared KO mice with Mettl21c LacZ/+ (HET) mice. Realtime
qPCR confirmed the efficiency of Mettl21c deletion in KO mice (Figure 4.20A). KO mice were
indistinguishable from HET mice in gross morphology, body weight and SOL muscle weight
(Figure 4.21A-B). Total numbers and sizes of myofibers in SOL muscles were also comparable
between HET and KO mice (Figure 4.21C-D). However, KO mice trended to run a shorter
distance than HET mice (Figure 4.21E). Interestingly, immunostaining of Myh isoforms showed
that the percentage of type I myofibers in SOL muscle was comparable between HET and KO
mice (Figure 4.22A-B). Similarly, Mettl21c KO did not affect the number of type I myofibers in
TA and EDL muscles (Figure 4.23). These results indicate that Mettl21e does not affect
myofiber type specification, consistent to the temporal expression of Mettl21e in mature
myofibers.
We then asked if Mettl21e KO affect the protein levels of Hspa8 and MEF2 in adult SOL
muscles. We found that Mettl21cKO indeed reduced the level of Hspa8 in sarcoplasm and
increased the protein levels of MEF2A and MEF2D in myonuclei (Figure 4.20B), without
affecting the mRNA levels of MEF2 (Figure 4.20B). Despite the increased levels of nuclear
MEF2A and MEF2D, the expressions of slow muscle related genes Pgc1a and Myh7 only
trended to increase without reaching a significant level in whole muscles (Figure 4.24A),
potentially due to mixture of >60% type II myofibers in the muscle. To confirm this speculation,
we isolated individual type I myofibers from SOL muscles of HET and KO mice, and found that
the expressions of Pgc1α and Myh7 in KO myofibers were significantly increased by 75% and
26%, respectively (Figure 4.24B). We conclude from these results that Mettl21c represses the
level and activity of MEF2A and MEF2D to control the expression of slow muscle related genes
in adult muscles.
Muscle gene expression and myofiber type are also controlled by nerve innervation. We
therefore denervated the sciatic nerves of the hindlimbs to determine the effect of Mettl21c on
myofiber type without complication of neuronal influence (Figure 4.25A-B). At 14 days after
denervation, KO mice had more I/IIa hybrid myofibers (co-stained by Myh7 and Myh2) in the
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SOL muscles than did HET mice (Figure 4.25A-B). In addition, percentages of type I myofibers
were increased and percentages of type IIa myofibers were decreased in KO mice compared to
HET mice after denervation (Figure 4.25C). Similar changes in myofiber types were observed in
EDL and TA muscles of KO and HET mice (Figure 4.26). At the molecular level, loss of
Mettl21c decreased the levels of Hspa8 and Myh7, and increased the levels of MEF2A and
MEF2D (Figure 4.27A), accompanied by upregulation of slow muscle related genes in the
denervated SOL muscles of KO mice (Figure 4.27B). Taken as a whole, our study establishes a
model in which Mettl21c methylates and stabilizes Hspa8, which selectively targets MEF2A and
MEF2D for degradation through the CMA pathway, and thus suppressing the slow muscle gene
program.

Relative mRNA levels

Relative mRNA levels

Relative mRNA levels
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Figure 4.1 Mettl21c is enriched in type I myofibers of the skeletal muscle
(A) Quantitative PCR (qPCR) showing relative mRNA levels of Mettl21c in different tissues. (B)
qPCR analysis of Mettl21c in fast-twitch (TA, EDL and GA) and slow-twitch (SOL) muscles.
Error bars represent mean+s.d. of 6 mice. (C) qPCR analysis of Mettl21c in different types of
myofibers isolated from SOL and EDL muscles of 4 mice. * or different letters indicate p < 0.05
(Student’s t-test).
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Figure 4.2 Expression analysis of Mettl21c using Mettl21cLacZ/+ mice
(A) Genetic targeting of Mettl21c through insertion of LacZ into exons 2-5. Grey box indicate
the exon of Mettl21c gene, and blue box indicate LacZ gene. (B) X-gal staining of different
skeletal muscles. A part of Mettl21cLacZ/+ diaphragm in box is enlarged to show the LacZ+
myofibers. (C) Immunostaining of Myh7 (type I myofibers, Red) and Myh2 (type IIa myofibers,
Green), and X-gal staining of serial sections of SOL muscles isolated from Mettl21cLacZ/+ mice.
Scale bar: 100 µm.
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Figure 4.3 The expression of Mettl21c in skeletal muscles
Immunostaining of Myh7 and Myh2, and X-gal staining of serial sections of GA, EDL and TA
muscles isolated from Mettl21cLacZ/+ mice. Scale bar: 100 µm.
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Figure 4.4 Whole mount X-gal staining of E18.5 embryo

Relative mRNA levels
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Figure 4.5 Expression of Mettl21c during muscle development
(A-C) Immunostaining of Myh7 (Red) and Dystrophin (Green), and X-gal staining of serial
sections of SOL muscles of postnatal day (P) 3 (A), P7 (B) and P10 (C) Mettl21cLacZ/+ mice.
Scale bar: 100 µm. (D) qPCR analysis of Mettl21c in different developmental stage. Error bars
represent mean+s.d. of 5 mice. Different letters indicate p < 0.05 (Student’s t-test).
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Figure 4.6 Expression of Mettl21c in EDL muscles during muscle development
Immunostaining of Myh7 (Red) and Dystrophin (Green), and X-gal staining of serial sections of
EDL muscles of P10 and P14 Mettl21cLacZ/+ mice. Scale bar: 100 µm.

Relative mRNA levels
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Figure 4.7 Expression of Mettl21c in SOL muscles during muscle regeneration
(A) Realtime qPCR analysis of Mettl21c at different days during SOL muscle regeneration. Error
bars represent mean+s.d. of 6 mice. Different letters indicate p < 0.05 (Student’s t-test). (B-C)
Immunostaining of Myh7 (Red) and Myh2 (Green), and X-gal staining of serial sections of SOL
muscles at day 7 (B) and day 14 (C) after CTX injection. Scale bar: 100 µm.

Relative mRNA levels
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HET KO
Figure 4.8 Expression of Mettl21c during in vitro myogenesis
(A) Bright field image of X-gal stainings of differentiated myoblasts isolated from Mettl21cLacZ/+
mice at different days after differentiation induction. Scale bar: 50 µm. (B) qPCR analysis of
Mettl21c in differentiated myoblasts isolated from Mettl21cLacZ/+ or Mettl21cLacZ/LacZ mice. Error
bars represent mean+s.d. of 5 independent biological experiments.
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Figure 4.9 Analysis of Mettl21c binding proteins using mass spectrometry
(A) Construction of a flagged Mettl21c overexpression plasmid (Mettl21c-FLAG) and its
intracellular localization (Red) after transfected into C2C12 myoblasts. (B) Flow chat of the
analysis of Mettl21c binding proteins using mass spectrometry. (C) Coomassie stained SDSPAGE of proteins pulled down by the FLAG antibody from primary myoblasts transduced with
Mettl21c-FLAG or GFP-FLAG adenoviral vectors.
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Figure 4.10 Mettl21c binds with Hspa8
(A) Mass spectrometry analysis of Mettl21c binding proteins. (B) Detection of Hspa8 in
Mettl21c-FLAG protein complex after immunoprecipitation from myoblasts. The lysates of
myoblasts was set as a positive control to indicate the position of Hspa8.
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Figure 4.11 Analysis of methylated peptides
(A) Flow chat of the analysis of methylated peptides. (B) MS/MS fragmentation pattern of
Hspa8 peptide. The b- and y-ions supports trimethylation of Hspa8 at K561. (C) Chromatogram
view for the trimethylated Hspa8 peptide in myoblasts transduced with Mettl21c-GFP
(Mettl21cOE) or GFP only (as control) adenoviral vectors.

90

Figure 4.12 In vitro methylation assay
Methylation assay using 293A lysates transfected with different plasmids. Top, fluorography of
reaction complex after SDS-PAGE separation; Bottom, western blot of indicated proteins in
reaction complex.
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Figure 4.13 Methylation status of Hspa8 in SOL muscles of WT or Mettl21c LacZ/LacZ mice
Chromatogram view for the di- or trimethylated Hspa8 peptide in SOL muscles of WT or
Mettl21cLacZ/LacZ mice.
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Figure 4.14 Methylation stabilizes Hspa8
(A) Western blots analysis of mutated Hspa8 after cycloheximide-induced inhibition of
translation. (B) Luciferase assays showing the effects of Hspa8 on the transcriptional activity of
MEF2A, MEF2C and MEF2D using the 3xMEF2-luc reporter. Error bars represent mean+s.d. of
5 independent biological experiments. * indicates p < 0.05 (Student’s t-test).

Relative mRNA levels
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Figure 4.15 Hspa8 decreases the level of MEF2A and MEF2C
(A) Western blots analysis showing the effect of Hspa8 overexpression (Hspa8 OE) on Myh7,
MEF2A and MEF2D proteins in myotubes. Primary myoblasts were induced to differentiate for
2 days and then were transduced with Hspa8OE or control adenoviral vectors for 3 more days. (D)
qPCR analysis of slow muscle related genes in Hspa8OE or control myotubes. Error bars
represent mean+s.d. of 5 independent biological experiments. * indicates p < 0.05 (Student’s ttest).

94

Figure 4.16 Hspa8 decreases the level of Myh7 in myotubes
(A-B) Immunostaining (A) and quantification (B) of Myh7 (Red) in control and Hspa8 OE
myotubes. Scale bar: 50 µm. Error bars represent mean+s.d. of 5 independent biological
experiments. * indicates p < 0.05 (Student’s t-test).

Relative mRNA levels
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Figure 4.17 Mettl21c decreases the level of Myh7 in myotubes
(A) Realtime qPCR analysis of Mettl21c in myoblasts. (B-C) Immunostaining (B) and
quantification (C) of Myh7 (Red) in differentiated myoblasts transduced with Mettl21c-GFP
(Mettl21cOE) or GFP only (as control) adenoviral vectors. Primary myoblasts were induced to
differentiate for 2 days and then were transduced with Mettl21c OE or control adenoviral vectors
for 3 more days. Scale bar: 50 µm. Error bars represent mean+s.d. of 5 independent biological
experiments. * indicates p < 0.05 (Student’s t-test).

Relative mRNA levels
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Figure 4.18 Mettl21c decreases the level of MEF2A and MEF2D
(A) Western blots analysis of indicated proteins in control and Mettl21c OE myotubes. (B)
Realtime qPCR analysis of slow muscle related genes. Scale bar: 50 µm. Error bars represent
mean+s.d. of 5 independent biological experiments. * indicates p < 0.05 (Student’s t-test).
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Figure 4.19 Western blots analysis of indicated proteins in control and Mettl21c OE
myotubes after Lamp2 knockdown
Primary myoblasts were treated with lentivirus for 2 days and selected in puromycin (1 μg/ml)
for 2 additional days. These primary myoblasts were then transduced with Mettl21c OE or control
adenoviral vectors. Two days after adenoviral transduction, the myoblasts were induced to
differentiate for 3 days.

Relative mRNA levels
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Figure 4.20 Mettl21cKO leads to increased levels of MEF2
(A) Realtime qPCR analysis of Mettl21c in Mettl21cLacZ/+ (HET) and Mettl21cLacZ/LacZ (KO) mice.
(B) Western blots analysis of indicated proteins in sarcoplasm and myonuclei proteins of SOL
muscles. Error bars represent mean+s.d. of 7 mice. * indicates p < 0.05 (Student’s t-test).
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Figure 4.21 Analysis of Mettl21cLacZ/+ and Mettl21cLacZ/LacZ mice
(A) Relative body weight and (B) SOL muscle weight of HET and KO mice. (C) Myofiber
numbers in SOL muscles of HET and KO mice. (D) Myofiber size in SOL muscles of HET and
KO mice. (D) Running distance of HET and KO mice in treadmill test. Error bars represent
mean+s.d. of 7 mice. * indicates p < 0.05 (Student’s t-test).
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Figure 4.22 Myofiber types in SOL muscles of HET and KO mice
(A) Immunostaining of Myh7 (Red) and Myh2 (Green) in SOL muscles of HET or KO mice.
Scale bar: 500 µm. (B) Quantification of different types of myofibers in SOL muscles of HET or
KO mice.
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Figure 4.23 The number of type I myofibers in EDL and TA muscles
Immunostaining of Myh7 (Red) and Myh2 (Green) and quantification of types I myofibers in
EDL and TA muscles of HET or KO mice. Error bars represent mean+s.d. of 7 mice. Scale bar:
100 µm.
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Figure 4.24 Loss of Mettl21c upregulates the expression of Pgc1α and Myh7
(A) qPCR analysis of slow muscle related genes in SOL muscles of HET or KO mice. Error bars
represent mean+s.d. of 7 mice. (B) qPCR analysis of MEF2 target genes in type I myofibers
from SOL muscles of HET or KO mice. * indicates p < 0.05 (Student’s t-test).
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Figure 4.25 Type I myofiber is increased in denervated SOL muscles of Mettl21c KO mice
(A) Immunostaining of Myh7 (Red) and Myh2 (Green) in denervated SOL muscle of HET or
KO mice. Scale bar: 250 µm. Regions in squares are enlarged in (B). (B) The number of I/IIa
hybrid myofibers in denervated SOL muscle of HET or KO mice. Arrows indicate I/IIa hybrid
myofibers. (C) Quantification of different types of myofibers in denervated SOL muscles of HET
or KO mice. Error bars represent mean+s.d. of 7 mice. * indicates p < 0.05 (Student’s t-test).
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Figure 4.26 The number of type I myofibers in denervated EDL and TA muscles
Immunostaining of Myh7 (Red) and Myh2 (Green) and quantification of types I myofibers in
denervated EDL and TA muscles of HET or KO mice. Scale bar: 100 µm. Error bars represent
mean+s.d. of 7 mice. * indicates p < 0.05 (Student’s t-test).
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Figure 4.27 The levels of MEF2A and MEF2C in denervated SOL muscles of Mettl21c KO
mice
(A) Western blots analysis of indicated proteins. (B) qPCR analysis of slow muscle related genes
in denervated SOL muscles of HET or KO mice. Error bars represent mean+s.d. of 7 mice. *
indicates p < 0.05 (Student’s t-test).
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4.4

Discussion

In this study we dissect the in vivo function of a type I myofiber-specific methyltransferase
Mettl21c, which catalyzes non-histone protein methylation of Hspa8 to control an autophagy
pathway in the muscle. The bridge between Mettl21c and autophagy is Hspa8. In humans,
METTL21C interacts with multiple Hsp70s (Cloutier et al., 2013). We not only identified Hspa8
as a substrate of Mettl21c in mice, but also pinpointed K561 as the specific residue being
trimethylated by Mettl21c. Intriguingly, Jakobsson et al. reported that human HSPA8, which
shares similar primary structure with murine Hspa8, is trimethylated at K561 by METTL21A, a
paralog of METTL21C (Jakobsson et al., 2013). A potential compensatory role of murine
Mettl21a in trimethylating Hspa8 could be used to explain why Mettl21c KO only partially
blocks the trimethylation of Hspa8. Interestingly, Hspa8 is also dimethylated at K561 in skeletal
muscles, but dimethylation of Hspa8 is not mediated by Mettl21c as deletion of Mettl21c leads to
increased levels of dimethylated Hspa8 in the KO mice. Although what dimethylate Hsp8a is
unclear, SETD1A has been reported to dimethylate K561 of Hspa1, a paralog of Hspa8 (Cho et
al., 2012).
At the functional level, K561 methylation of Hspa8 reduces its affinity for α-Syn, whose
aggregation leads to Parkinson’s disease (Jakobsson et al., 2013). K561 methylation of Hspa8
also decreases its affinity for the E3 ligase, CHIP, and thus reduces the ubiquitination of Hspa8
(Zhang et al., 2015). The latter event indicates that methylation prevents ubiquitin-mediated
proteasomal degradation of Hspa8. Indeed, we show that the mimic of dimethylated Hspa8 has
better stability than unmethylated Hspa8. In addition, Mettl21cOE increases the trimethylation of
Hspa8 and its total levels. In contrast, Mettl21cKO decreases the trimethylation of Hspa8 and its
total levels. Our current data show that either trimethylation or dimethylation stabilizes Hspa8.
Hspa8 is a key regulator in the CMA pathway (Cuervo and Wong, 2014). It selectively
recognizes KFERQ-like motif-containing proteins, including MEF2A and MEF2D, and shuttles
them to lysosome for degradation. The degradation of MEF2A and MEF2D is blocked by
interrupting their interactions with Hspa8 in neuronal cells (Yang et al., 2009; Zhang et al., 2014).
Here, we identify a similar role of Hspa8 in skeletal muscles, by demonstrating that Mettl21c OE
reduced the levels of MEF2A and MEF2D through Hspa8-mediated autophagy. Blockage of the
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CMA pathway rescued MEF2A and MEF2D levels in Mettl21c OE muscle cells. Our studies thus
link Mettl21c to CMA. The link is further strengthened by our observation that Mettl21c KO
mimics the inhibition of CMA to increase the levels of MEF2A and MEF2D. Increased MEF2A
and MEF2D promote slow myofiber formation (Czubryt et al., 2003; Potthoff et al., 2007b).
Notably, we only found myofiber-type switch in denervated skeletal muscles, indicating that the
effect of motor neuron innervation has a more dominant role than Mettl21c in fiber type
determination. Motor neurons trigger electrical stimulus and also release neurotrophic substance
to regulate myofiber identity (Gundersen, 1998). The importance of neuronal influence has been
shown by the cross-innervation experiment, in which transplanting nerves from fast muscles to
slow muscles is sufficient to drive slow to fast myofiber switching, and vice versa (Buller et al.,
1960).
Most myofiber-type specific proteins play a positive role in the maintenances of myofiber
identity. Positive regulators of myofiber types include ephrin-A3 (Stark et al., 2015), PGC1α
(Lin et al., 2002), Tbx15 (Lee et al., 2015), and Sox6 (Quiat et al., 2011). In contrast, Mettl21c is
specifically expressed in slow myofibers, but acts as a negative regulator of slow muscle genes.
This inhibitory effect is similar to myostatin (Mstn), a fast muscle-enriched protein playing a role
in limiting fast myofiber formation (Allen and Loh, 2011; Carlson et al., 1999; Wang et al.,
2012). The expression of Mettl21c is absent during myogenesis to allow the expression of slow
muscle genes. Once slow muscle development or regeneration is completed, Mettl21c is then
increased to constrain the levels of MEF2 transcription factors, whose elevated expression
interferes with normal muscle function (Wu and Olson, 2002). Consistently, we found that
Mettl21cLacZ/LacZ mice had slightly reduced exercise endurance. Although loss of Mstn promotes
protein synthesis and inhibits protein degradation in muscles (Garber, 2016), it impairs muscle
function and diminishes exercise capacity (Amthor et al., 2007; Mouisel et al., 2014). Hence, cell
type and developmental stage dependent control of protein abundance is crucial for optimal
muscle function.
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CHAPTER 5.

5.1

CONCLUDING REMARKS AND FUTURE WORKS

The biological roles of Mettl21e and Mettl21c in muscle

Gene expression is usually associated with its function, although not always. I first noticed
Mettl21e due to its upregulated expression in hypertrophic muscle. Then, I checked the
expressions of Mettl21e and its family members (Mettl21a-d) in different tissues, and found that
only Mettl21e and Mettl21c were specifically expressed in skeletal muscles (Figure 3.2A, 4.1A,
5.1). This is the main reason why I choose to study the role of Mettl21e and Mettl21c in skeletal
muscles.
Mettl21 family is a newly identified methyltransferase family (Cloutier et al., 2013; Kernstock et
al., 2012). The substrates of human METTL21A, METTL21B, and METTL21D have been
identified (Cloutier et al., 2013; Hamey et al., 2017; Jakobsson et al., 2013; Kernstock et al.,
2012; Malecki et al., 2017), however the in vivo function of these proteins are not determined.
My study thus aims to uncover the in vivo function of Mettl21e and Mettl21c.
I found that Mettl21e was enriched in type IIb myofibers. Mettl21e could inhibit the proteasome
activity to prevent the degradation of proteins and thus contribute to the large size of type IIb
myofibers (Figure 5.2). The in vivo function of Mettl21e is verified by the increased myofiber
size in transgenic mice with Mettl21e overexpression, and by the decreased type IIb myofiber
size in Mettl21e knockout mice.
In contrast to the fast myofiber protein Mettl21e, Mettl21c is a slow myofiber specific protein.
Mettl21c methylates Hspa8 at K561 to interrupt its binding with an E3-ligase CHIP, and to
prevent its ubiquitination and proteasome-dependent degradation (Figure 5.3). Hspa8 carries
MEF2A and MEF2D to lysosome for degradation in chaperone mediated autophagy pathway
(Figure 5.3). Thus, Mettl21c has a function to limit the levels of MEF2A and MEF2D. The
function of Mettl21c is verified by the Mettl21c knockout mice which have increased levels of
MEF2A and MEF2D and increased expressions of MEF2-targeted genes. The biological
significance of Mettl21c relies on its temporal expression during muscle development. Mettl21c
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is absent during myogenesis, allowing the high levels of MEF2A and MEF2D which are required
for myogenesis. In mature type I myofibers, Mettl21c is expressed to limit the levels of MEF2A
and MEF2D to avoid hyperactivated MEF2-induced myotonia.

5.2

Functional diversity of the Mettl21 proteins

My study not only extends the understanding of the roles of myofiber-specific proteins, but also
sheds light on the functional diversity of the Mettl21 proteins. Current studies prove that human
METTL21 proteins methylate different substrates. My study indicates that Mettl21e and
Mettl21c have different biological roles.
Mettl21 proteins are grouped together in phylogenetic analysis according to their primary
sequences, but the function of METTL21/Mettl21 proteins cannot be solely deduced from the
sequences. Phylogenetic analysis shows that Mettl21c, Mettl21e and human METTL21C are
grouped together, indicating that their primary sequences are relatively similar to each other
(Figure 5.4). However, functionally, Mettl21c and Human METTL21A are close, with a
common substrate (Jakobsson et al., 2013). It is possible that their 3D structures are more
functionally related than linear structure.

5.3

Future works

It remains to be determined how Mettl21e regulates 26S proteasome activity. It is possible that
Mettl21e methylates the subunits of proteasome to affect their posttranslational modification, or
to modulate their protein-protein interactions. Mettl21e may also methylates proteasome-binding
molecular chaperones to indirectly regulate proteasome activity. To study the detailed
mechanism, I will identify the substrate protein and the methylation site, and then find out the
effect of the methylation on substrate protein stability, posttranslational modification and
protein-protein interactions. These studies will further extend our knowledge about proteasome
activity regulation and will open new avenues for preventing human muscle mass loss.
It will be interesting to compare the promoters of Mettl21e, Mettl21c and the other myofiber
type-specific genes. This analysis may uncover myofiber type-specific cis-regulatory elements,
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leading to the discovery of other myofiber type-specific genes. In addition, I found that some
type I myofibers did not express Mettl21c in fast-twitch muscles (Figure 4.6), indicating that
there are factors regulating the heterogeneity of type I myofibers in fast muscles. It will be
interesting to analyze the proteomics of individual type I myofibers in fast muscles. The
proteomic analysis may lead to discovery of the factors controlling myofiber heterogeneity. The
ultimate goal is to fully understand the molecular mechanisms of myofiber identity establishment.
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Figure 5.1 The expression of Mettl21 genes in different tissues
Error bars represent mean+s.d. of 7 mice.
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Figure 5.2 Diagram summarizing the role of Mettl21e in type IIb myofibers
Mettl21e increases myofiber size through inhibiting protein degradation in proteasome
dependent pathway.
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Figure 5.3 Diagram summarizing the role of Mettl21c in type I myofibers
Mettl21c methylates Hspa8 at K561 to interrupt its binding with an E3-ligase CHIP, and to
prevent its ubiquitination and proteasome-dependent degradation. The surviving Hspa8 carries
MEF2A and MEF2D to lysosome for degradation in chaperone mediated autophagy pathway
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METTL21A
METTL21B
METTL21D
Mettl21e
METTL21C
Mettl21c
METTL23
METTL22
FAM86A
CAMKMT
METTL20
METTL18

Figure 5.4 Phylogenetic tree containing Mettl21e, Mettl21c and human MTF16 proteins
Human MTF16 proteins are capitalized. Mouse Mettl21e and Mettl21c are highlighted by dots.
Values on the line are bootstrap values showing percentage confidence of relatedness.
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